INDEX TO AUTHORS

A

ADAMS, L. S. See SULLIVAN, JERRY, ROWDEN, LEWIS, PITZELE, LAW, ADAMS, LE THI, and SHEA 1557

ALEXANDER, ELAINE, and HENKART, PIERRE. The adherence of human Fc receptor-bearing lymphocytes to antigen-antibody complexes. II. Morphologic alterations induced by the substrate 329

ALLEN, F. H. See RUBINSTEIN, SUCIU-FOCA, NICHOLSON, FOTINO, MOLINARO, HARISIADIS, HARDY, REEMTSMA, and ALLEN 1277

ALTER, B. J., GRILLOT-COURVALIN, C., BACH, M. L., ZIER, K. S., SONDEL, P. M., and BACH, F. H. Secondary cell-mediated lympholysis: importance of *H-2* LD and SD factors 1005

ANDERS, R. F., NORDSTOGA, K., NATVIG, J. B., and HUSBY, G. Amyloid-related serum protein SAA in endotoxin-induced amyloidosis of the mink 678

ANDRES, GIUSEPPE A. See BIGAZZI, KOSUDA, HSU, and ANDRES 382

ANTHONY, BASCOM F. Immunity to the Group B streptococci: interaction of serum and macrophages with types Ia, Ib, and Ic 1186

ASWANIKUMAR, SRIVINIVESABHATT. See SHOWELL, FREER, ZIGMOND, SCHIFFMANN, ASWANIKUMAR, CORCORAN, and BECKER 1154

B

BACH, FRITZ H. See ALTER, GRILLOT-COURVALIN, BACH, ZIER, SONDEL, and BACH 1005

—. See KUPERMAN and BACH 1545

BACH, M. L. See ALTER, GRILLOT-COURVALIN, BACH, ZIER, SONDEL, and BACH 1005

BAKER, CAROL J., KASPER, DENNIS L., and DAVIS, CHARLES E. Immunochemical characterization of the "native" type III polysaccharide of Group B *Streptococcus* 258

BALLET, JEAN-JACQUES, INSEL, RICHARD, MERLER, EZIO, and ROSEN, FRED S. Inhibition of maturation of human precursor lymphocytes by coformycin, an inhibitor of the enzyme adenosine deaminase 1271

BALTIMORE, DAVID. See Rosenberg and Baltimore 1453

BANG, F. B. See WEISER and BANG 690

BASCH, ROSS S. See KADISH and BASCH 1082

BEACHEY, EDWIN H., and OFEK, ITZHAK. Epithelial cell binding of group A streptococci by lipoteichoic acid on fimbriae denuded of M protein 759

BECKER, ELMER L. See SHOWELL, FREER, ZIGMOND, SCHIFFMANN, ASWANIKUMAR, CORCORAN, and BECKER 1154

BECKER, M. See MÄKELÄ, JULIN, and BECKER 316

BENACERRAF, BARUJ. See DORF, MAURER, MERRYMAN, and BENACERRAF 889

—. See KATZ, DORF, and BENACERRAF 906

—. See SCHWARTZ, DORF, BENACERRAF, and PAUL 897

BENNETT, MICHAEL. See KUMAR, CARUSO, and BENNETT 728

—. See KUMAR and BENNETT 713

BEREK, C. See BLACK, HÄMMERLING, BEREK, RAJEWSKY, and EICHMANN 846

—. See HÄMMERLING, BLACK, BEREK, EICHMANN, and RAJEWSKY 861

BEUTLER, E., KUHL, W., MATSUMOTO, F., and PANGALIS, G. Acid hydrolases in leukocytes and platelets of normal subjects and in patients with Gaucher's and Fabry's disease 975

BEVAN, MICHAEL JOHN. Cross-priming for a secondary cytotoxic response to minor H antigens with *H-2* congenic cells which do not cross-react in the cytotoxic assay 1283

BIGAZZI, PIERLUIGI E., KOSUDA, LINDA L., HSU, KONRAD C., and ANDRES, GIUSEPPE A. Immune complex orchitis in vasectomized rabbits 382

BILLINGTON, W. D. See SEARLE, SELLENS, ELSON, JENKINSON, and BILLINGTON 348

BLACK, S. J., HÄMMERLING, G. J., BEREK, C., RAJEWSKY, K., and EICHMANN, K. Idiotypic analysis of lymphocytes in vitro. I. Specificity and heterogeneity of B and T lymphocytes reactive with anti-idiotypic antibody 846

—. See HÄMMERLING, BLACK, BEREK, EICHMANN, and RAJEWSKY 861

BLANDEN, R. V. See KEES and BLANDEN 450

—. See PANG and BLANDEN 469

BODEL, PHYLLIS. Colchicine stimulation of pyrogen production by human blood leukocytes 1015

BOLOGNESI, DANI P. See METZGAR, MOHANAKUMAR, and BOLOGNESI 47

BONNARD, GUY D., MANDERS, ERNEST K., CAMPBELL, DARRELL wa., JR., HERBERMAN, RONALD B., and COLLINS, MICHAEL J., JR. Immunosuppressive activity of a subline of the mouse EL-4 lymphoma. Evidence for minute virus of mice causing the inhibition 187

BOYSE, EDWARD A. See CANTOR, SHEN, and BOYSE 1391
—. See IKEDA, ROWE, BOYSE, STOCKERT, SATO, and JACOBS 32
—. See TUNG, SHEN, FLEISSNER, and BOYSE 969
BRAUN, DIETMAR G., QUINTÁNS, JOSÉ, LUZZATI, ALMA L., LEFKOVITS, IVAN, and READ, STANLEY E. Antibody response of rabbit blood lymphocytes in vitro. Kinetics, clone size, and clonotype analysis in response to streptococcal group polysaccharide antigens 360
—. See FROST, BRAUN, POSKITT, CAHILL, and TRNKA 707

C

CAHILL, R. N. P., FROST, H., and TRNKA, Z. The effects of antigen on the migration of recirculating lymphocytes through single lymph nodes 870
—. See FROST, BRAUN, POSKITT, CAHILL, and TRNKA 707
CALKINS, CATHERINE E., ORBACH-ARBOUYS, SIMONE, STUTMAN, O., and GERSHON, R. K. Cell interactions in the suppression of in vitro antibody responses 1421
CAMPBELL, DARRELL A., JR. See BONNARD, MANDERS, CAMPBELL, HERBERMAN, and COLLINS 187
CANTOR, H., SHEN, FUNG-WIN, and BOYSE, EDWARD A. Separation of helper T cells from suppressor T cells expressing different Ly components. II. Activation by antigen: after immunization, antigen-specific suppressor and helper activities are mediated by distinct T-cell subclasses 1391
—. See HUBER, DEVINSKY, GERSHON, and CANTOR 1534
—. See JANDINSKI, CANTOR, TADAKUMA, PEAVY, and PIERCE 1382
CARPENTER, CHARLES B. See SOULILLOU, CARPENTER, D'APICE, and STROM 405
CARUSO, TOM. See KUMAR, CARUSO, and BENNETT 728
CHAPITIS, JANE, and LEPOW, IRWIN H. Multiple sedimenting species of properdin in human serum and interaction of purified properdin with the third component of complement 241
CHESEBRO, BRUCE, and WEHRLY, KATHY. Studies on the role of the host immune response in recovery from Friend virus leukemia. I. Antiviral and antileukemia cell antibodies 73
— and —. II. Cell-mediated immunity 85
CHIANG, CHINLEE. See KLEIN, GEIB, CHIANG, and HAUPTFELD 1439
CHILLER, JACQUES M. See SKIDMORE, CHILLER, WEIGLE, RIBLET, and WATSON 143
CIFONE, M. See STANLEY, CIFONE, HEARD, and DEFENDI 631
COHEN, LEONARD, HOLZMAN, ROBERT S., VALENTINE, FRED, T., and LAWRENCE, H. SHERWOOD. Requirement of precommitted cells as targets for the augmentation of lymphocyte proliferation by leukocyte dialysates 791
COHN, ZANVIL. See NOGUEIRA and COHN 1402
COLLEY, DANIEL G. Adoptive suppression of granuloma formation 696
COLLINS, MICHAEL J., JR. See BONNARD, MANDERS, CAMPBELL, HERBERMAN, and COLLINS 187
COLTEN, HARVEY R. See EINSTEIN, SCHNEEBERGER, and COLTEN 114
COOPER, NEIL R. See PERRIN, JOSEPH, COOPER, and OLDSTONE 1027
CORCORAN, BARBARA. See SHOWELL, FREER, ZIGMOND, SCHIFFMANN, ASWANIKUMAR, CORCORAN, and BECKER 1154
COUTINHO, ANTONIO. See MÖLLER, GRONOWICZ, PERSSON, COUTINHO, MÖLLER, HAMMARSTRÖM, and SMITH 1429
—. See SMITH, HAMMARSTRÖM, and COUTINHO 1521
CZOP, JOYCE, and NUSSENZWEIG, VICTOR. Studies on the mechanism of solubilization of immune precipitates by serum 615

D

DANIEL, MARY R. See DAVIES, TAYLOR, DANIEL, and WAKERLEY 987
D'APICE, ANTHONY J. F. See SOULILLOU, CARPENTER, D'APICE, and STROM 405
DAVID, CHELLA, MEO, TOMMASO, MCCORMICK, JOHN, and SHREFFLER, DONALD C. Expression of individual Ia specificities on T and B cells. I. Studies with mitogen-induced blast cells 218
DAVIES, A. J. S. See DOENHOFF and DAVIES 660
DAVIES, HUGH FF. S., TAYLOR, JUDITH E., DANIEL, MARY R., and WAKERLEY, CORINNE. Differences between pig tissues in the expression of major transplantation antigens: possible relevance for organ allografts 987
DAVIS, CHARLES E. See BAKER, KASPER, and DAVIS 258
DEFENDI, V. See STANLEY, CIFONE, HEARD, and DEFENDI 631
DEL VILLANO, BERT C. See LERNER, WILSON, DEL VILLANO, MCCONAHEY, and DIXON 151
DESTEFANO, M. J. See RABINOVITCH and DESTEFANO 290
DEVINSKY, O. See HUBER, DEVINSKY, GERSHON, and CANTOR 1534
DIENER, E., KRAFT, N., LEE, K-C., and SHIOZAWA, C. Antigen recognition. IV. Discrimination by antigen-binding immunocompetent B cells between immunity and tolerance is determined by adherent cells 805
DINE, MARY S. See NIEDERHUBER, FRELINGER, DINE, SHOFFNER, DUGAN, and SHREFFLER 372
DIXON, FRANK J. See LERNER, WILSON, DEL VILLANO, MCCONAHEY, and DIXON 151
DOENHOFF, M. J., and DAVIES, A. J. S. The

capacity of mitogen-responsive T cells to "home" to their tissue of origin, analyzed by means of chromosome makers 660
DORF, MARTIN E., MAURER, PAUL H., MERRYMAN, CARMEN F., and BENACERRAF, BARUJ. Inclusion group systems and *cis-trans* effects in responses controlled by the two complementing *Ir-GLΦ* genes 889
—. See KATZ, DORF, and BENACERRAF 906
—. See SCHWARTZ, DORF, BENACERRAF, and PAUL 897
DUGAN, ELIZABETH. See NIEDERHUBER, FRELINGER, DINE, SHOFFNER, DUGAN, and SHREFFLER 372
DUTTON, RICHARD W. See TSE and DUTTON 1199
DWYER, J. M., ROSENBAUM, J. T., and LEWIS, S. The effect of anti-mu suppression of γM and γG on the production of γE 781

E

EARDLEY, D. D., STASKAWICZ, M. O., and GERSHON, R. K. Suppressor cells: dependence on assay conditions for functional activity 1211
EBERT, JAMES D. See OZATO and EBERT 1
EDELMAN, GERALD M. See SCHRADER and EDELMAN 601
—. See SELA, WANG, and EDELMAN 665
EGGERS, HANS J. Successful treatment of enterovirus-infected mice by 2-(α-hydroxybenzyl)-benzimidazole and guanidine 1367
EICHMANN, K. See BLACK, HÄMMERLING, BEREK, RAJEWSKY, and EICHMANN 846
—. See HÄMMERLING, BLACK, BEREK, EICHMANN, and RAJEWSKY 861
EINSTEIN, L. PETER, SCHNEEBERGER, EVELINE E., and COLTEN, HARVEY R. Synthesis of the second component of complement by long-term primary cultures of human monocytes 114
ELLIOTT, BRUCE E. See NAGY, ELLIOTT, NABHOLZ, KRAMMER, and PERNIS 648
ELSON, J. See SEARLE, SELLENS, ELSON, JENKINSON, and BILLINGTON 348

F

FALK, J. A. See TAUBER, FALK, FALK, and ZABRISKIE 1341
FALK, R. E. See TAUBER, FALK, FALK, and ZABRISKIE 1341
FERGUSON, RONALD M., SCHMIDTKE, JON R., and SIMMONS, RICHARD L. Differential effects of chlorpromazine on the in vitro generation and effector function of cytotoxic lymphocytes 232
FESTENSTEIN, H. See MATOSSIAN-ROGERS and FESTENSTEIN 456
FIDLER, JOHN M., HOWARD, MAUREEN C., and SHORTMAN, KEN. Antigen-initiated B-lymphocyte differentiation. VIII. Sedimentation velocity and buoyant density characterization of virgin antibody-forming cell progenitors in the adoptive immune response of unprimed CBA mice to 4-hydroxy-3-iodo-5-nitrophenylacetic acid-polymerized bacterial flagellin antigen 1220
FLEISSNER, ERWIN. See TUNG, SHEN, FLEISNER, and BOYSE 969
FORMAN, JAMES. See VITETTA, FORMAN, and KETTMAN 1055
FORNI, GUIDO, SHEVACH, ETHAN M., and GREEN, IRA. Mutant lines of guinea pig L2C leukemia. I. Deletion of Ia alloantigens is associated with a loss in immunogenicity of tumor-associated transplantation antigens 1067
FOTINO, M. See RUBINSTEIN, SUCIU-FOCA, NICHOLSON, FOTINO, MOLINARO, HARISIADIS, HARDY, REEMTSMA, and ALLEN 1277
FREER, RICHARD J. See SHOWELL, FREER, ZIGMOND, SCHIFFMANN, ASWANIKUMAR, CORCORAN, and BECKER 1154
FRELINGER, JEFFREY A. See NIEDERHUBER, FRELINGER, DINE, SHOFFNER, DUGAN, and SHREFFLER 372
FROST, H., BRAUN, D. G., POSKITT, D., CAHILL, R. N. P., and TRNKA, Z. Antipolyssaccharide antibodies of restricted heterogeneity secreted by a single lymph node 707
—. See CAHILL, FROST, and TRNKA 870

G

GEIB, ROY. See KLEIN, GEIB, CHIANG, and HAUPTFELD 1439
GERSHON, R. K. See CALKINS, ORBACH-ARBOUYS, STUTMAN, and GERSHON 1421
—. See EARDLEY, STASKAWICZ, and GERSHON 1211
—. See HUBER, DEVINSKY, GERSHON, and CANTOR 1534
GOIDL, EDMOND A., KLASS, JANET, and SISKIND, GREGORY W. Ontogeny of B-lymphocyte function. II. Ability of endotoxin to increase the heterogeneity affinity of the immune response of B lymphocytes from fetal mice 1503
GOLUB, EDWARD S. See ROMAN and GOLUB 482
GOOD, ROBERT A. See SHOU, SCHWARTZ, and GOOD 1100
GOTSCHLICH, EMIL C. See JOHNSTON, HOLMES, and GOTSCHLICH 741
GREEN, IRA. See FORNI, SHEVACH, and GREEN 1067
GRILLOT-COURVALIN, C. See ALTER, GRILLOT-COURVALIN, BACH, ZIER, SONDEL, and BACH 1005
GRONOWICZ, EVA. See MÖLLER, GRONOWICZ, PERSSON, COUTINHO, MÖLLER, HAMMARSTRÖM, and SMITH 1429
GUTHRIE, LINDA A. See JOHNSTON, LEHMEYER, and GUTHRIE 1551

H

HÄMMERLING, G. J., BLACK, S. J., BEREK, C., EICHMANN, K., and RAJEWSKY, K. Idiotypic

analysis of lymphocytes in vitro. II. Genetic control of T-helper cell responsiveness to anti-idiotypic antibody 861
—. See BLACK, HÄMMERLING, BEREK, RAJEWSKY, and EICHMANN 846
HAMMARSTRÖM, LENNART. See MÖLLER, GRONOWICZ, PERSSON, COUTINHO, MÖLLER, HAMMARSTRÖM, and SMITH 1429
—. See SMITH, HAMMARSTRÖM, and COUTINHO 1521
HARDY, M. A. See RUBINSTEIN, SUCIU-FOCA, NICHOLSON, FOTINO, MOLINARO, HARISIADIS, HARDY, REEMTSMA, and ALLEN 1277
HARISIADIS, L. See RUBINSTEIN, SUCIU-FOCA, NICHOLSON, FOTINO, MOLINARO, HARISIADIS, HARDY, REEMTSMA, and ALLEN 1277
HAUPTFELD, VĚRA. See KLEIN, GEIB, CHIANG, and HAUPTFELD 1439
HEARD, P. M. See STANLEY, CIFONE, HEARD, and DEFENDI 631
HEBER-KATZ, ELLEN, and WILSON, DARCY B. Sheep red blood cell-specific helper activity in rat thoracic duct lymphocyte populations positively selected for reactivity to specific strong histocompatibility alloantigens 701
HENKART, PIERRE. See ALEXANDER and HENKART 329
HENNEY, CHRISTOPHER S. See KUPPERS and HENNEY 684
HENSON, PETER M. Activation and desensitization of platelets by platelet-activating factor (PAF) derived from IgE-sensitized basophils. Characteristics of the secretory response 937
— and OADES, ZENAIDA G. Activation of platelets by platelet-activating factor (PAF) derived from IgE-sensitized basophils. II. The role of serine proteases, cyclic nucleotides, and contractile elements in PAF-induced secretion 953
HERBERMAN, RONALD B. See BONNARD, MANDERS, CAMPBELL, HERBERMAN, and COLLINS 187
HOLMES, KING K. See JOHNSTON, HOLMES, and GOTSCHLICH. 741
HOLZMAN, ROBERT S. See COHEN, HOLZMAN, VALENTINE, and LAWRENCE 791
HOWARD, MAUREEN C. See FIDLER, HOWARD, and SHORTMAN 1220
HSU, KONRAD C. See BIGAZZI, KOSUDA, HSU, and ANDRES 382
HUBER, B., DEVINSKY, O., GERSHON, R. K., and CANTOR, H. Cell-mediated immunity: delayed-type hypersensitivity and cytotoxic responses are mediated by different T-cell subclasses 1534
HUDSON, L., and SPRENT, J. Specific adsorption of IgM antibody onto H-2-activated mouse T lymphocytes 444
HUSBY, G. See ANDERS, NORDSTOGA, NATVIG, and HUSBY 678

I

IKEDA, HISAMI, ROWE, WALLACE P., BOYSE, EDWARD A., STOCKERT, ELISABETH, SATO, HIDETOSHI, and JACOBS, SHELLEY. Relationship of infectious murine leukemia virus and virus-related antigens in genetic crosses between AKR and the *Fv-1* compatible strain C57L 32
INMAN, JOHN K. See REHN, SHEARER, KOREN, and INMAN 127
INNES, JUDITH B. See KUNTZ, INNES, and WEKSLER 1042
INSEL, RICHARD. See BALLET, INSEL, MERLER, and ROSEN 1271

J

JACOBS, SHELLEY. See IKEDA, ROWE, BOYSE, STOCKERT, SATO, and JACOBS 32
JANDINSKI, J., CANTOR, H., TADAKUMA, T., PEAVY, D. L., and PIERCE, C. W. Separation of helper T cells from suppressor T cells expressing different Ly components. I. Polyclonal activation: suppressor and helper activities are inherent properties of distinct T-cell subclasses 1382
JENKINSON, E. J. See SEARLE, SELLENS, ELSON, JENKINSON, and BILLINGTON 348
JERRY, L. M. See SULLIVAN, JERRY, ROWDEN, LEWIS, PITZELE, LAW, ADAMS, LE THI, and SHEA 1557
JOHNSTON, KENNETH H., HOLMES, KING K., and GOTSCHLICH, EMIL C. The serological classification of *Neisseria gonorrhoeae*. I. Isolation of the outer membrane complex responsible for serotypic specificity 741
JOHNSTON, RICHARD B., JR., LEHMEYER, JOYCE E., and GUTHRIE, LINDA. Generation of superoxide anion and chemiluminescence by human monocytes during phagocytosis and on contact with surface-bound immunoglobulin G 1551
JONDAL, MIKAEL. See KIESSLING, PETRANYI, KÄRRE, JONDAL, TRACEY, and WIGZELL 772
JOSEPH, BARRY S. See PERRIN, JOSEPH, COOPER, and OLDSTONE 1027
JULIN, MARJA. See MÄKELÄ, JULIN, and BECKER 316

K

KABAT, ELVIN A. See PEREIRA and KABAT 422
KADISH, JULIAN L., and BASCH, ROSS S. Hematopoietic thymocyte precursors. I. Assay and kinetics of the appearance of progeny 1082
KANG, ANDREW H. See POSTLETHWAITE and KANG 1299
KÄRRE, KLAS. See KIESSLING, PETRANYI, KÄRRE JONDAL, TRACEY, and WIGZELL 772
KASK, ANNE M. See SCHWARTZ, KASK, PAUL, and SHEVACH 541
KASPER, DENNIS L. See BAKER, KASPER, and DAVIS 258
KATZ, DAVID H., DORF, MARTIN E., and BENACERRAF, BARUJ. Control of T-lymphocyte and B-lymphocyte activation by two complementing *Ir-GLΦ* immune response genes 906
KEES, URSULA, and BLANDEN, R. V. A single

genetic element in *H-2K* affects mouse T-cell antiviral function in poxvirus infection 450
KELLER, ROBERT H., and TOMASI, THOMAS B., JR. Alpha-fetoprotein synthesis by murine lymphoid cells in allogeneic reactions 1140
KETTMAN, JOHN R. See VITETTA, FORMAN, and KETTMAN 1055
KIBRICK, SIDNEY. See WEBB, LORIA, MADGE, and KIBRICK 1239
KIESSLING, ROLF, PETRANYI, GYÖZÖ, KÄRRE, KLAS, JONDAL, MIKAEL, TRACEY, DANIEL, and WIGZELL, HANS. Killer cells: a functional comparison between natural, immune T-cell and antibody-dependent in vitro systems 772
KINCADE, PAUL W., RALPH, PETER, and MOORE, MALCOLM A. S. Growth of B-lymphocyte clones in semisolid culture is mitogen dependent 1265
KINDT, THOMAS J. See SOGN and KINDT 1475
KIRSTEIN, DAVID P. See NORTH, KIRSTEIN, and TUTTLE 559, 574
KLASS, JANET. See GOIDL, KLASS, and SISKIND 1503
KLEIN, JAN, GEIB, ROY, CHIANG, CHINLEE, and HAUPTFELD, VĚRA. Histocompatibility antigens controlled by the *I* region of the murine *H-2* complex. I. Mapping of *H-2A* and *H-2C* loci 1439
KLINMAN, NORMAN R. See METCALF and KLINMAN 1327
KOJIMA, SOMEI. See WATANABE, KOJIMA, and OVARY 833
KOLB, WILLIAM P., and MÜLLER-EBERHARD, HANS J. The membrane attack mechanism of complement: the three polypeptide chain structure of the eighth component (C8) 1131
KOREN, HILLEL S. See REHN, SHEARER, KOREN, and INMAN 127
KOSUDA, LINDA L. See BIGAZZI, KOSUDA, HSU, and ANDRES 382
KRAFT, N. See DIENER, KRAFT, LEE, and SHIOZAWA 805
KRAMMER, PETER H. See NAGY, ELLIOTT, NABHOLZ, KRAMMER, and PERNIS 648
KUHL, W. See BEUTLER, KUHL, MATSUMOTO, and PANGALIS 975
KUMAR, VINAY, and BENNETT, MICHAEL. Mechanisms of genetic resistance to Friend virus leukemia in mice. II. Resistance of mitogen-responsive lymphocytes mediated by marrow-dependent cells 713
—, CARUSO, TOM, and BENNETT, MICHAEL. III. Susceptibility of mitogen-responsive lymphocytes mediated by T cells 728
KUNTZ, MARY M., INNES, JUDITH B., and WEKSLER, MARC E. Lymphocyte transformation induced by autologous cells. IV. Human T-lymphocyte proliferation induced by autologous or allogeneic non-T lymphocytes 1042
KUPERMAN, ODED J., and BACH, FRITZ H. Cellular basis of neonatal induction of in vitro tolerance 1545
KUPPERS, RUDOLF, C., and HENNEY, CHRISTOPHER S. Evidence for direct linkage between antigen recognition and lytic expression in effector T cells 684

L

LAIR, STEPHEN. See LOZZIO, MACHADO, LOZZIO, and LAIR 225
LAW, T. See SULLIVAN, JERRY, ROWDEN, LEWIS, PITZELE, LAW, ADAMS, LE THI, and SHEA 1557
LAWRENCE, H. SHERWOOD. See COHEN, HOLZMAN, VALENTINE, and LAWRENCE 791
LAYTON, JUDITH E. See NOSSAL and LAYTON 511
LEE, K-C. See DIENER, KRAFT, LEE, and SHIOZAWA 805
LEFKOVITS, IVAN. See BRAUN, QUINTÁNS, LUZZATI, LEFKOVITS, and READ 360
—. See SPRENT and LEFKOVITS 1289
LEHMEYER, JOYCE E. See JOHNSTON, LEHMEYER, and GUTHRIE 1551
LEPOW, IRWIN H. See CHAPITIS and LEPOW 241
LERNER, RICHARD A., WILSON, CURTIS B., DEL VILLANO, BERT C., MCCONAHEY, PATRICIA J., and DIXON, FRANK J. Endogenous oncornaviral gene expression in adult and fetal mice: quantitative, histologic, and physiologic studies of the major viral glycoprotein, gp70 151
LESKOWITZ, SIDNEY. See STADECKER and LESKOWITZ 206
LE THI, See SULLIVAN, JERRY, ROWDEN, LEWIS, PITZELE, LAW, ADAMS, LE THI, and SHEA 1557
LEWIS, M. G. See SULLIVAN, JERRY, ROWDEN, LEWIS, PITZELE, LAW, ADAMS, LE THI, and SHEA 1557
LEWIS, S. See DWYER, ROSENBAUM, and LEWIS 781
LORIA, ROGER M. See WEBB, LORIA, MADGE, and KIBRICK 1239
LOZZIO, BISMARCK B., MACHADO, EMILIO A., LOZZIO, CARMEN B., and LAIR, STEPHEN. Hereditary asplenic-athymic mice: transplantation of human myelogenous leukemic cells 225
LOZZIO, CARMEN B. See LOZZIO, MACHADO, LOZZIO, and LAIR 225
LUZZATI, ALMA L. See BRAUN, QUINTÁNS, LUZZATI, LEFKOVITS, and READ 360

M

MACHADO, EMILIO A. See LOZZIO, MACHADO, LOZZIO, and LAIR 225
MADGE, GORDON E. See WEBB, LORIA, MADGE, and KIBRICK 1239
MÄKELÄ, O., JULIN, MARJA, and BECKER, M. Inheritance of antibody specificity. III. A new V_H gene controls fine specificity of anti-*p*-azobenzenearsonate coupled to the carbon atom 5 of hydroxyphenylacetic acid in the mouse 316
MANDERS, ERNEST K. See BONNARD, MANDERS, CAMPBELL, HERBERMAN, and COLLINS 187
MARBROOK, J. See SKINNER and MARBROOK 1562

MARCUS, DONALD M. See STEIN-DOUGLAS, SCHWARTING, NAIKI, and MARCUS 822
MASON, D. W. The requirement for C3 receptors on the precursors of 19S and 7S antibody-forming cells 1111
—. The class of surface immunoglobulin on cells carrying IgG memory in rat thoracic duct lymph: the size of the subpopulation mediating IgG memory 1122
MATOSSIAN-ROGERS, A., and FESTENSTEIN, H. Modification of murine T-cell cytotoxicity by preimmunization with *M* locus and *H-2* incompatibilities 456
MATSUMOTO, F. See BEUTLER, KUHL, MASUMOTO, and PANGALIS 975
MAURER, PAUL H. See DORF, MAURER, MERRYMAN, and BENACERRAF 889
MCCONAHEY, PATRICIA J. See LERNER, WILSON, DEL VILLANO, MCCONAHEY, and DIXON 151
MCCORMICK, JOHN. See DAVID, MEO, MCCORMICK, and SHREFFLER 218
MCINTYRE, PATRICIA A. See TSAN and MCINTYRE 1308
MEO, TOMMASO. See DAVID, MEO, MCCORMICK, and SHREFFLER 218
MERLER, EZIO. See BALLET, INSEL, MERLER, and ROSEN 1271
MERRYMAN, CARMEN F. See DORF, MAURER, MERRYMAN, and BENACERRAF 889
METCALF, ELEANOR S., and KLINMAN, NORMAN R. In vitro tolerance induction of neonatal murine B cells 1327
METZGAR, RICHARD S., MOHANAKUMAR, T., and BOLOGNESI, DANI P. Relationships between membrane antigens of human leukemic cells and oncogenic RNA virus structural components 47
MICKEY, M. RAY. See TING, MICKEY, and TERASKAKI 981
MILLER, J. F. A. P. See SPRENT and MILLER 585
MOHANAKUMAR, T. See METZGAR, MOHANAKUMAR, and BOLOGNESI 47
MOLINARO, A. See RUBINSTEIN, SUCIU-FOCA, NICHOLSON, FOTINO, MOLINARO, HARISIADIS, HARDY, REEMTSMA, and ALLEN 1277
MÖLLER, ERNA. See MÖLLER, GRONOWICZ, PERSSON, COUTINHO, MÖLLER, HAMMARSTRÖM, and SMITH 1429
—. See SOLHEIM, THORSBY, and MÖLLER 1568
MÖLLER, GÖRAN, GRONOWICZ, EVA, PERSSON, ULLA, COUTINHO, ANTONIO, MÖLLER, ERNA, HAMMARSTRÖM, LENNART, and SMITH, EDVARD. Spleen cells from animals tolerant to a thymus-dependent antigen can be activated by lipopolysaccharide to synthesize antibodies against the tolerogen 1429
MONGINI, PATRICIA K. A., and ROSENBERG, LEON T. Inhibition of lymphocyte trapping by a passenger virus in murine ascitic tumors: characterization of lactic dehydrogenase virus (LDV) as the inhibitory component and analysis of the mechanism of inhibition 100
MOORE, MALCOLM A. S. See KINCADE, RALPH, and MOORE 1265
MOORE, MALCOLM A. S. See RALPH, MOORE, and NILSSON 1528
MORRIS, BEDE. See PEARSON, SIMPSON-MORGAN, and MORRIS 167
MORSE, JANE H. See MORSE and MORSE 1483
MORSE, STEPHEN I., and MORSE, JANE H. Isolation and properties of the leukocytosis- and lymphocytosis-promoting factor of *Bordetella pertussis* 1483
MOSHER, DEANE F., and WING, DAVID A. Synthesis and secretion of α_2-macroglobulin by cultured human fibroblasts 462
MÜLLER-EBERHARD, HANS J. See KOLB and MÜLLER-EBERHARD 1131
MUNTHE-KAAS, AMY C. See REFSNES and MUNTHE-KAAS 1464

N

NABHOLZ, MARKUS. See NAGY, ELLIOTT, NABHOLZ, KRAMMER, and PERNIS 648
NAGY, ZOLTAN, ELLIOTT, BRUCE E., NABHOLZ, MARKUS, KRAMMER, PETER H., and PERNIS, BENVENUTO. Specific binding of alloantigens to T cells activated in the mixed lymphocyte reaction 648
NAIKI, MASAHARU. See STEIN-DOUGLAS, SCHWARTING, NAIKI, and MARCUS 822
NATVIG, JACOB B. See ANDERS, NORDSTOGA, NATVIG, and HUSBY 678
—. See SLETTEN, WESTERMARK, and NATVIG 993
NICHOLSON, J. F. See RUBINSTEIN, SUCIU-FOCA, NICHOLSON, FOTINO, MOLINARO, HARISIADIS, HARDY, REEMTSMA, and ALLEN 1277
NIEDERHUBER, JOHN E., FRELINGER, JEFFREY A., DINE, MARY S., SHOFFNER, PATRICIA, DUGAN, ELIZABETH, and SHREFFLER, DONALD C. Effects of anti-Ia sera on mitogenic responses. II. Differential expression of the Ia marker on phytohemagglutinin- and concanavalin A-reactive T cells 372
NILSSON, KENNETH. See RALPH, MOORE, and NILSSON 1528
NOGUEIRA, NADIA, and COHN, ZANVIL. *Trypanosoma cruzi:* mechanism of entry and intracellular fate in mammalian cells 1402
NORDSTOGA, K. See ANDERS, NORDSTOGA, NATVIG, and HUSBY 678
NORTH, ROBERT J., KIRSTEIN, DAVID P., and TUTTLE, RICHARD L. Subversion of host defense mechanisms by murine tumors. I. A circulating factor that suppresses macrophage-mediated resistance to infection 559
—, —, and —. II. Counter-influence of concomitant antitumor immunity 574
NOSSAL, G. J. V., and LAYTON, JUDITH E. Antigen-induced aggregation and modulation of receptors on hapten-specific B lymphocytes 511
NOTKINS, ABNER LOUIS. See YOON and NOTKINS 1170
NUSSENZWEIG, VICTOR. See CZOP and NUSSENZWEIG 615

O

OADES, ZENAIDA G. See HENSON and OADES 953
OFEK, ITZHAK. See BEACHEY and OFEK 759
OLDSTONE, MICHAEL B. A. See PERRIN, JOSEPH, COOPER, and OLDSTONE 1027
ORBACH-ARBOUYS, SIMONE. See CALKINS, ORBACH-ARBOUYS, STUTMAN, and GERSHON 1421
OVARY, ZOLTAN. See WATANABE, KOJIMA, and OVARY 833
OZATO, KEIKO, and EBERT, JAMES D. Concanavalin A potentiates syngeneic response in murine lymphocytes 1

P

PANG, T., and BLANDEN, R. V. Regulation of the T-cell response to ectromelia virus infection. I. Feedback suppression by effector T cells 469
PANGALIS, G. See BEUTLER, KUHL, MATSUMOTO, and PANGALIS 975
PAUL, WILLIAM E. See SCHWARTZ, DORF, BENACERRAF, and PAUL 897
—. See SCHWARTZ, KASK, PAUL, and SHEVACH 541
—. See SCHWARTZ and PAUL 529
PEARSON, LEONARD D., SIMPSON-MORGAN, MAX W., and MORRIS, BEDE. Lymphopoiesis and lymphocyte recirculation in the sheep fetus 167
PEAVY, D. L. See JANDINSKI, CANTOR, TADAKUMA, PEAVY, and PIERCE 1382
PEREIRA, MIERCIO E. A., and KABAT, ELVIN A. Immunochemical studies on blood groups. LXII. Fractionation of hog and human A, H, and AH blood group active substance on insoluble immunoadsorbents of *Dolichos* and *Lotus* lectins 422
PERNIS, BENVENUTO. See NAGY, ELLIOTT, NABHOLZ, KRAMMER, and PERNIS 648
PERRIN, LUC H., JOSEPH, BARRY S., COOPER, NEIL R., and OLDSTONE, MICHAEL B. A. Mechanism of injury of virus-infected cells by antiviral antibody and complement: participation of IgG, $F(ab')_2$, and the alternative complement pathway 1027
—. See THEOFILOPOULOS and PERRIN 271
PERSSON, ULLA. See MÖLLER, GRONOWICZ, PERSSON, COUTINHO, MÖLLER, HAMMARSTRÖM, and SMITH 1429
PETRANYI, GYÖZÖ. See KIESSLING, PETRANYI, KÄRRE, JONDAL, TRACEY, and WIGZELL 772
PFIZENMAIER, K., STARZINSKI-POWITZ, A., RODT, H., RÖLLINCHOFF, M., and WAGNER, H. Virus and trinitrophenol hapten-specific T-cell-mediated cytotoxicity against H-2 incompatible target cells 999
PIERCE, C. W. See JANDINSKI, CANTOR, TADAKUMA, PEAVY, and PIERCE 1382
PITZELE, R. See SULLIVAN, JERRY, ROWDEN, LEWIS, PITZELE, LAW, ADAMS, LE THI, and SHEA 1557
POLLEY, M. J. See TAUBER, POLLEY, and ZABRISKIE 1352
PONTÉN, JAN. See VAHERI, RUOSLAHTI, WESTERMARK, and PONTÉN 64
POOLE, TIMOTHY W. See SILVERS, WACHTEL, and POOLE 1317
POSKITT, D. See FROST, BRAUN, POSKITT, CAHILL, and TRNKA 707
POSTLETHWAITE, ARNOLD E., and KANG, ANDREW H. Collagen- and collagen peptide-induced chemotaxis of human blood monocytes 1299

Q

QUINTÁNS, JOSÉ. See BRAUN, QUINTÁNS, LUZZATI, LEFKOVITS, and READ 360

R

RABINOVITCH, M., and DESTEFANO, M. J. Cell shape changes induced by cationic anesthetics 290
RAJEWSKY, K. See BLACK, HÄMMERLING, BEREK, RAJEWSKY, and EICHMANN 846
—. See HÄMMERLING, BLACK, BEREK, EICHMANN, and RAJEWSKY 861
RALPH, PETER, MOORE, MALCOLM A. S., and NILSSON, KENNETH. Lysozyme synthesis by established human and murine histiocytic lymphoma cell lines 1528
—. See KINCADE, RALPH, and MOORE 1265
READ, STANLEY E. See BRAUN, QUINTÁNS, LUZZATI, LEFKOVITS, and READ 360
REDELMAN, DOUG, SCOTT, CHARLES B., SHEPPARD, HAYNES W., JR., and SELL, STEWART. In vitro studies of the rabbit immune system. V. Suppressor T cells activated by concanavalin A block the proliferation, not the induction of antierythrocyte plaque-forming cells 919
REEMTSMA, K. See RUBINSTEIN, SUCIU-FOCA, NICHOLSON, FOTINO, MOLINARO, HARISIADIS, HARDY, REEMTSMA, and ALLEN 1277
REFSNES, KARIN, and MUNTHE-KAAS, AMY C. Introduction of B-chain-inactivated ricin into mouse macrophages and rat Kupffer cells via their membrane Fc receptors 1464
REHN, TERRY G., SHEARER, GENE M., KOREN, HILLEL S., and INMAN, JOHN K. Cell-mediated lympholysis of *N*-(3-nitro-4-hydroxy-5-iodophenylacetyl)-β-alanyl-glycylglycyl-modified autologous lymphocytes. Effector cell specificity to modified cell surface components controlled by the *H-2K* and *H-2D* serological regions of the murine major histocompatibility complex 127
RIBLET, ROY. See SKIDMORE, CHILLER, WEIGLE, RIBLET, and WATSON 143
RICH, ROBERT R. See RICH and RICH 672
RICH, SUSAN SOLLIDAY, and RICH, ROBERT R. Regulatory mechanisms in cell-mediated immune responses. III. *I*-region control of suppressor cell interaction with responder cells in mixed lymphocyte reactions 672

RODT, H. See PFIZENMAIER, STARZINSKI-POWITZ, RODT, RÖLLINGHOFF, and WAGNER 999
ROGERS, JOHN C. Characterization of DNA excreted from phytohemagglutinin-stimulated lymphocytes 1249
RÖLLINGHOFF, M. See PFIZENMAIER, STARZINSKI-POWITZ, RODT, RÖLLINGHOFF, and WAGNER 999
ROMAN, JANET M., and GOLUB, EDWARD S. Leukemia in AKR mice. I. Effects of leukemic cells on antibody-forming potential of syngeneic and allogeneic normal cells 482
ROMBALL, CAROLE G., and WEIGLE, WILLIAM O. Modulation of regulatory mechanisms operative in the cyclical production of antibody 497
ROSEN, FRED. See BALLET, INSEL, MERLER, and ROSEN 1271
ROSENBAUM, J. T. See DWYER, ROSENBAUM, and LEWIS 781
ROSENBERG, LEON T. See MONGINI and ROSENBERG 100
ROSENBERG, NAOMI, and BALTIMORE, DAVID. A quantitative assay for transformation of bone marrow cells by Abelson murine leukemia virus 1453
ROWDEN, G. See SULLIVAN, JERRY, ROWDEN, LEWIS, PITZELE, LAW, ADAMS, LE THI, and SHEA 1557
ROWE, WALLACE P. See IKEDA, ROWE, BOYSE, STOCKERT, SATO, and JACOBS 32
RUBINSTEIN, P., SUCIU-FOCA, N., NICHOLSON, J. F., FOTINO, M., MOLINARO, A., HARISIADIS, L., HARDY, M. A., REEMTSMA, K., and ALLEN, F. H., JR. The HLA system in the families of patients with juvenile diabetes mellitus 1277
RUOSLAHTI, ERKKI. See VAHERI, RUOSLAHTI, WESTERMARK, and PONTÉN 64

S

SACHS, DAVID H. See SCHMITT-VERHULST, SACHS, and SHEARER 211
SASSA, SHIGERU. Sequential induction of heme pathway enzymes during erythroid differentiation of mouse Friend leukemia virus-infected cells 305
SATO, HIDETOSHI. See IKEDA, ROWE, BOYSE, STOCKERT, SATO, and JACOBS 32
SCHIFFMANN, ELLIOT. See SHOWELL, FREER, ZIGMOND, SCHIFFMANN, ASWANIKUMAR, CORCORAN, and BECKER 1154
SCHMIDTKE, JON R. See FERGUSON, SCHMIDTKE, and SIMMONS 232
SCHMITT-VERHULST, ANNE-MARIE, SACHS, DAVID H., and SHEARER, GENE M. Cell-mediated lympholysis of trinitrophenyl-modified autologous lymphocytes. Confirmation of genetic control of response to trinitrophenyl-modified H-2 antigens by the use of anti-H-2 and anti-Ia antibodies 211
SCHNEEBERGER, EVELINE E. See EINSTEIN, SCHNEEBERGER, and COLTEN 114
SCHRADER, JOHN W., and EDELMAN, GERALD M. Participation of the H-2 antigens of tumor cells in their lysis by syngeneic T cells 601
SCHREINER, GEORGE F., and UNANUE, EMIL R. Calcium-sensitive modulation of Ig capping: evidence supporting a cytoplasmic control of ligand-receptor complexes 15
SCHWARTING, GERALD A. See STEIN-DOUGLAS, SCHWARTING, NAIKI, and MARCUS 822
SCHWARTZ, BENJAMIN D., KASK, ANNE M., PAUL, WILLIAM E., and SHEVACH, ETHAN M. Structural characteristics of the alloantigens determined by the major histocompatibility complex of the guinea pig 541
SCHWARTZ, RONALD H., DORF, MARTIN E., BENACERRAF, BARUJ, and PAUL, WILLIAM E. The requirement for two complementing *Ir-GL*Φ immune response genes in the T-lymphocyte proliferative response to poly-(Glu^{53}Lys^{36}-Phe^{11}) 897
– and PAUL, WILLIAM E. T-lymphocyte-enriched murine peritoneal exudate cells. II. Genetic control of antigen-induced T-lymphocyte proliferation 529
SCHWARTZ, STANLEY. See SHOU, SCHWARTZ, and GOOD 1100
SCOTT, CHARLES B. See REDELMAN, SCOTT, SHEPPARD, and SELL 919
SEARLE, R. F., SELLENS, M. H., ELSON, J., JENKINSON, E. J., and BILLINGTON, W. D. Detection of alloantigens during preimplantation development and early trophoblast differentiation in the mouse by immunoperoxidase labeling 348
SELA, BEN-AMI, WANG, JOHN L., and EDELMAN, GERALD M. Lymphocyte activation by monovalent fragments of antibodies reactive with cell surface carbohydrates 665
SELL, STEWART. See REDELMAN, SCOTT, SHEPPARD, and SELL 919
SELLENS, M. H. See SEARLE, SELLENS, ELSON, JENKINSON, and BILLINGTON 348
SHEA, M. See SULLIVAN, JERRY, ROWDEN, LEWIS, PITZELE, LAW, ADAMS, LE THI, and SHEA 1557
SHEARER, GENE M. See REHN, SHEARER, KOREN, and INMAN 127
–. See SCHMITT-VERHULST, SACHS, and SHEARER 211
SHEN, FUNG-WIN. See CANTOR, SHEN, and BOYSE 1391
–. See TUNG, SHEN, FLEISSNER, and BOYSE 969
SHEPPARD, HAYNES W., JR. See REDELMAN, SCOTT, SHEPPARD, and SELL 919
SHEVACH, ETHAN M. See FORNI, SHEVACH, and GREEN 1067
–. See SCHWARTZ, KASK, PAUL, and SHEVACH 541
SHIOZAWA, C. See DIENER, KRAFT, LEE, and SHIOZAWA 805

SHOFFNER, PATRICIA. See NIEDERHUBER, FRELINGER, DINE, SHOFFNER, DUGAN, and SHREFFLER 372
SHORTMAN, KEN. See FIDLER, HOWARD, and SHORTMAN 1220
SHOU, LIEN, SCHWARTZ, STANLEY A., and GOOD, ROBERT A. Suppressor cell activity after concanavalin A treatment of lymphocytes from normal donors 1100
SHOWELL, HENRY J., FREER, RICHARD J., ZIGMOND, SALLY H., SCHIFFMANN, ELLIOT, ASWANIKUMAR, SRIVINIVESABHATT, CORCORAN, BARBARA, and BECKER, ELMER L. The structure-activity relations of synthetic peptides as chemotactic factors and inducers of lysosomal enzyme secretion for neutrophils 1154
SHREFFLER, DONALD C. See DAVID, MEO, MCCORMICK, and SHREFFLER 218
–. See NIEDERHUBER, FRELINGER, DINE, SHOFFNER, DUGAN, and SHREFFLER 372
SILVERS, WILLYS K., WACHTEL, STEPHEN S., and POOLE, TIMOTHY W. The behavior of Sk-incompatible skin grafts on mice rendered tolerant at birth with lymphoid cells 1317
SIMMONS, RICHARD L. See FERGUSON, SCHMIDTKE, and SIMMONS 232
SIMPSON-MORGAN, MAX W. See PEARSON, SIMPSON-MORGAN, and MORRIS 167
SISKIND, GREGORY W. See GOIDL, KLASS, and SISKIND 1503
SKIDMORE, BARRY J., CHILLER, JACQUES M., WEIGLE, WILLIAM O., RIBLET, ROY, and WATSON, JAMES. Immunologic properties of bacterial lipopolysaccharide (LPS). III. Genetic linkage between the in vitro mitogenic and in vivo adjuvant properties of LPS 143
SKINNER, M. A., and MARBROOK, J. An estimation of the frequency of precursor cells which generate cytotoxic lymphocytes 1562
SKJOLD, STEPHEN. See TAGG, SKJOLD, and WANNAMAKER 1540
SLETTEN, KNUT, WESTERMARK, PER, and NATVIG, JACOB B. Characterization of amyloid fibril proteins from medullary carcinoma of the thyroid 993
SMITH, EDVARD, HAMMARSTRÖM, LENNART, and COUTINHO, ANTONIO. Association between mitogenicity and immunogenicity of 4-hydroxy-3,5-dinitrophenacetyl-lipopolysaccharide, a T-independent antigen 1521
–. See MÖLLER, GRONOWICZ, PERSSON, COUTINHO, MÖLLER, HAMMARSTRÖM, and SMITH 1429
SOGN, JOHN A., and KINDT, THOMAS J. A genetic polymorphism in the constant region of rabbit b4 kappa chains 1475
SOLHEIM, BJARTE, THORSBY, ERIK, and MÖLLER, ERNA. Inhibition of the Fc receptor of human lymphoid cells by antisera-recognizing determinants of the HLA system 1568
SONDEL, P. M. See ALTER, GRILLOT-COURVALIN, BACH, ZIER, SONDEL, and BACH 1005
SOULILLOU, JEAN-PAUL, CARPENTER, CHARLES B., D'APICE, ANTHONY J. F., and STROM, TERRY B. The role of nonclassical, Fc receptor-associated, Ag-B antigens (Ia) in rat allograft enhancement 405
SPRENT, J., and LEFKOVITS, I. Effect of recent antigen priming on adoptive immune responses. IV. Antigen-induced selective recruitment of recirculating lymphocytes to the spleen demonstrable with a microculture system 1289
– and MILLER, J. F. A. P. Effect of recent antigen priming on adoptive immune responses. III. Antigen-induced selective recruitment of subsets of recirculating lymphocytes reactive to *H-2* determinants 585
–. See HUDSON and SPRENT 444
STADECKER, MIGUEL, and LESKOWITZ, SIDNEY. Genetic control of cutaneous basophil hypersensitivity 206
STANLEY, E. R., CIFONE, M., HEARD, P. M., and DEFENDI, V. Factors regulating macrophage production and growth: identity of colony-stimulating factor and macrophage growth factor 631
STARZINSKI-POWITZ, A. See PFIZENMAIER, STARZINSKI-POWITZ, RODT, RÖLLINGHOFF, and WAGNER 999
STASKAWICZ, M. O. See EARDLEY, STASKAWICZ, and GERSHON 1211
STEIN-DOUGLAS, KATHRYN E., SCHWARTING, GERALD A., NAIKI, MASAHARU, and MARCUS, DONALD M. Gangliosides as markers for murine lymphocyte subpopulations 822
STOCKERT, ELISABETH. See IKEDA, ROWE, BOYSE, STOCKERT, SATO, and JACOBS 32
STROM, TERRY B. See SOULILLOU, CARPENTER, D'APICE, and STROM 405
STUTMAN, O. See CALKINS, ORBACH-ARBOUYS, STUTMAN, and GERSHON 1421
SUCIU-FOCA, N. See RUBINSTEIN, SUCIU-FOCA, NICHOLSON, FOTINO, MOLINARO, HARISIADIS, HARDY, REEMTSMA, and ALLEN 1277
SULLIVAN, A. K., JERRY, L. M., ROWDEN, G., LEWIS, M. G., PITZELE, R., LAW, T., ADAMS, L. S., LE THI, H., and SHEA, M. Fetal antigens on the surface of human lymphoid cells 1557

T

TADAKUMA, T. See JANDINSKI, CANTOR, TADAKUMA, PEAVY, and PIERCE 1382
TAGG, JOHN R., SKJOLD, STEPHEN, and WANNAMAKER, LEWIS W. Transduction of bacteriocin determinants in Group A streptococci 1540
TAUBER, J. W., FALK, J. A., FALK, R. E., and ZABRISKIE, J. B. Nonspecific complement activation by streptococcal structures. I. Reevaluation of HLA cytotoxicity inhibition 1341

TAUBER, J. W., POLLEY, M. J., and ZABRISKIE, J. B. II. Properdin-independent initiation of the alternative pathway 1352
TAYLOR, JUDITH E. See DAVIES, TAYLOR, DANIEL, and WAKERLEY 987
TERASAKI, PAUL I. See TING, MICKEY, and TERASAKI 981
THEOFILOPOULOS, ARGYRIOS N., and PERRIN, LUC H. Binding of components of the properdin system to cultured human lymphoblastoid cells and B lymphocytes 271
THORSBY, ERIK. See SOLHEIM, THORSBY, and MÖLLER 1568
TING, ALAN, MICKEY, M. RAY, and TERASAKI, PAUL I. B-lymphocyte alloantigens in Caucasians 981
TOMASI, THOMAS B. See KELLER and TOMASI 1140
TRACEY, DANIEL. See KIESSLING, PETRANYI, KÄRRE, JONDAL, TRACEY, and WIGZELL 772
TRNKA, Z. See CAHILL, FROST, and TRNKA 870
—. See FROST, BRAUN, POSKITT, CAHILL, and TRNKA 707
TSAN, MIN-FU, and MCINTYRE, PATRICIA A. The requirement for membrane sialic acid in the stimulation of superoxide production during phagocytosis by human polymorphonuclear leukocytes 1308
TSE, HARLEY, and DUTTON, RICHARD W. Separation of helper and suppressor T lymphocytes on a Ficoll velocity sedimentation gradient 1199
TUNG, JWU-SHENG, SHEN, FUNG-WIN, FLEISSNER, ERWIN, and BOYSE, EDWARD A. X-gp70: a third molecular species of the envelope protein gp70 of murine leukemia virus, expressed on mouse lymphoid cells 969
TUTTLE, RICHARD L. See NORTH, KIRSTEIN, and TUTTLE 559, 574

U

UNANUE, EMIL R. See SCHREINER and UNANUE 15

V

VAHERI, ANTTI, RUOSLAHTI, ERKKI, WESTERMARK, BENGT, and PONTÉN, JAN. A common cell-type specific surface antigen in cultured human glial cells and fibroblasts: loss in malignant cells 64
VALENTINE, FRED T. See COHEN, HOLZMAN, VALENTINE, and LAWRENCE 791
VITETTA, ELLEN S., FORMAN, JAMES, and KETTMAN, JOHN R. Cell surface immunoglobulin. XVIII. Functional differences of B lymphocytes bearing different surface immunoglobulin isotypes 1055

W

WACHTEL, STEPHEN S. See SILVERS, WACHTEL, and POOLE 1317
WAGNER, H. See PFIZENMAIER, STARZINSKI-POWITZ, RODT, RÖLLINGHOFF, and WAGNER 999
WAKERLEY, CORINNE. See DAVIES, TAYLOR, DANIEL, and WAKERLEY 987
WANG, JOHN L. See SELA, WANG, and EDELMAN 665
WANNAMAKER, LEWIS W. See TAGG, SKJOLD, and WANNAMAKER 1540
WATANABE, NAOHIRO, KOJIMA, SOMEI, and OVARY, ZOLTAN. Suppression of IgE antibody production in SJL mice. I. Nonspecific suppressor T cells 833
WATSON, JAMES. See SKIDMORE, CHILLER, WEIGLE, RIBLET, and WATSON 143
WEBB, STANLEY R., LORIA, ROGER M., MADGE, GORDON E., and KIBRICK, SIDNEY. Susceptibility of mice to Group B Coxsackie virus is influenced by the diabetic gene 1239
WEHRLY, KATHY. See CHESEBRO and WEHRLY 73, 85
WEIGLE, WILLIAM O. See ROMBALL and WEIGLE 497
—. See SKIDMORE, CHILLER, WEIGLE, RIBLET, and WATSON 143
WEISER, W., and BANG, F. B. Macrophages genetically resistant to mouse hepatitis virus converted in vitro to susceptible macrophages 690
WEKSLER, MARC E. See KUNTZ, INNES, and WEKSLER 1042
WESTERMARK, BENGT. See VAHERI, RUOSLAHTI, WESTERMARK, and PONTÉN 64
WESTERMARK, PER. See SLETTEN, WESTERMARK, and NATVIG 993
WIGZELL, HANS. See KIESSLING, PETRANYI, KÄRRE, JONDAL, TRACEY, and WIGZELL 772
WILSON, CURTIS B. See LERNER, WILSON, DEL VILLANO, MCCONAHEY, and DIXON 151
WILSON, DARCY B. See HEBER-KATZ and WILSON 701
WING, DAVID A. See MOSHER and WING 462

Y

YOON, JI-WON, and NOTKINS, ABNER LOUIS. Virus-induced diabetes mellitus. VI. Genetically determined host differences in the replication of encephalomyocarditis virus in pancreatic beta cells 1170

Z

ZABRISKIE, J. B. See TAUBER, FALK, FALK, and ZABRISKIE 1341
—. See TAUBER, POLLEY, and ZABRISKIE 1352
ZIER, K. S. See ALTER, GRILLOT-COURVALIN, BACH, ZIER, SONDEL, and BACH 1005
ZIGMOND, SALLY H. See SHOWELL, FREER, ZIGMOND, SCHIFFMANN, ASWANIKUMAR, CORCORAN, and BECKER 1154
ZINKERNAGEL, ROLF M. *H-2* compatibility requirement for virus-specific T-cell-mediated cytolysis. The *H-2K* structure involved is coded by a single cistron defined by $H\text{-}2K^b$ mutant mice 437

INDEX TO SUBJECTS

A

Abelson murine leukemia virus, bone marrow cell transformation, quantitative assay, 1453
Acid hydrolases, leukocytes and platelets, Gaucher's and Fabry's disease, 975
Adenosine deaminase, human precursor lymphocyte maturation, inhibition by coformycin, 1271
Adjuvant and mitogenic activity, genetic linkage between, bacterial lipopolysaccharide, 143
Alloantigen binding to T cells, mixed lymphocyte reaction, 648
– characteristics, major histocompatibility complex, guinea pig, 541
Alloantigens, B lymphocyte, Caucasians, 981
– during preimplantation development and trophoblast differentiation, immunoperoxidase labeling, 348
–, histocompatibility, thoracic duct lymphocytes reactive to, erythrocyte-specific helper activity, 701
–, Ia, and tumor-associated transplantation antigens, guinea pig L2C leukemia, 1067
–, skin, incompatible with skin grafts, 1317
Allogeneic non-T lymphocytes, induction of T-lymphocyte proliferation, 1042
– reactions, α-fetoprotein synthesis, murine lymphoid cells, 1140
– and syngeneic normal cells, effects of leukemic cells on antibody formation, 482
Allograft enhancement, role of Fc receptor-associated Ag-B antigens, 405
–, tissue differences, major transplantation antigens, pig, 987
Alternate pathway, properdin-independent initiation, nonspecific complement activation by streptococcal structures, 1352
Amyloid fibril proteins, thyroid medullary carcinoma, 993
Amyloidosis, endotoxin-induced, amyloid-related serum protein SAA, mink, 678
Anesthetics, cationic, cell shape changes, 290
Anion, superoxide, and chemiluminescence, human monocyte phagocytosis and contact with surface-bound immunoglobulin G, 1551
Antibodies, anti-*H-2* and anti-Ia, cell-mediated lympholysis of modified autologous lymphocytes, 211
–, antipolysaccharide, restricted heterogeneity, secretion by single lymph node, 707
–, antiviral and antileukemia, host immune response, recovery from Friend virus leukemia, 73
Antibodies, spleen, against thymus-dependent antigen, lipopolysaccharide activation, 1429
Antibody, anti-idiotypic, genetic control of T-helper cell response to, 861
–, anti-idiotypic, reaction with B and T lymphocytes, 846
–, antiviral, and complement, injury of virus-infected cells, role of IgG, Fab'2, and alternate complement pathway, 1027
– cyclical production, regulatory mechanisms, 497
– dependent cellular cytotoxicity and natural immune T cells, comparison of killer cells, 772
– formation, syngeneic and allogeneic normal cells, effects of leukemic cells, 482
– forming cells, 19S and 7S, C3 receptors, 1111
–, IgE, suppression, SJL mice, 833
–, IgM, adsorption onto *H-2*-activated T lymphocytes, 444
– monovalent fragments, cell surface carbohydrates, lymphocyte activation, 665
– response of blood lymphocytes to streptococcal Group A polysaccharide antigens, 360
– responses, in vitro suppression, cell interactions, 1421
– specificity inheritance, V_H gene control, azobenzenearsonate-hydroxyphenylacetic acid, 316
Antibody-antigen complexes, adherence of Fc receptor-bearing lymphocytes, 329
Antierythrocyte plaque-forming cells, effect of concanavalin A-activated suppressor T cells, 919
Antigen activation, T-cell suppressor and helper subclasses, 1391
–, effect on lymphocyte recirculation through single lymph nodes, 870
– effects on receptors, hapten-specific B lymphocytes, 511
– induction of T-lymphocyte proliferation, genetic control, murine peritoneal exudate, 529
– initiation of B-lymphocyte differentiation, adoptive immune response, 1220
– priming, effect on adoptive immune responses, lymphocyte recirculation to spleen, 1289
– priming, effect on adoptive immune responses, subsets of *H-2*-reactive T cells, 585
– recognition, immunocompetent B-cell discrimination between immunity and tolerance, role of adherent cells, 805
– recognition and lytic expression, effector T cells, 684

Antigen, surface, human glial cells and fibroblasts, loss in malignant cells, 64
–, thymus-dependent, lipopolysaccharide activation of, spleen cell antibodies against, 1429
–, T-independent, lipopolysaccharide, mitogenicity and immunogenicity, 1521
Antigen-antibody complexes, adherence of Fc receptor-bearing lymphocytes, 329
Antigens, Ag-B, Fc receptor-associated, role in allograft enhancement, 405
–, H, and *H-2* congenic cells, cross-priming for secondary cytotoxic response, 1283
–, *H-2*, lysis of tumor cells by syngeneic T cells, 601
–, histocompatibility, control by *I* region, mapping of *H-2A* and *H-2C* loci, 1439
–, membrane, human leukemic cells, relation to oncogenic RNA virus components, 47
–, polysaccharide, streptococcal Group A, antibody response of blood lymphocytes, 360
–, surface, fetal human lymphoid cells, 987
–, transplantation, tissue differences, pig, 987
–, transplantation, tumor-associated, and Ia alloantigens, guinea pig L2C leukemia, 1067
–, virus-related, and murine leukemia virus, relationship in genetic crosses, 32
Anti-mu suppression of γM and γG, effect on γE, 781
Antitumor immunity, subversion of host defense mechanism by tumor, 574
Ascites tumor, lactic dehydrogenase virus inhibition of lymphocyte trapping, 100
Assay conditions, function of suppressor cells, 1211
Azobenzenearsonate-hydroxyphenylacetic acid, V_H gene control of antibody specificity, 316

B

B cells, Ia specificity, mitogen-induced blast cells, 218
– cells, immunocompetent antigen-binding, discrimination between immunity and tolerance, role of adherent cells, 805
– cells, neonatal murine, tolerance induction, 1327
– lymphocyte alloantigens, Caucasians, 981
– lymphocyte clones, growth in semisolid culture, role of mitogen, 1265
– lymphocyte differentiation, antigen-initiated, adoptive immune response, 1220
– lymphocytes, fetal, endotoxin and increased heterogeneity of affinity of immune response, 1503
– lymphocytes, hapten-specific, antigen effects on receptors, 511
– lymphocytes and lymphoblastoid cells, human, binding of properdin components, 271
– lymphocytes, surface immunoglobulin isotypes, 1055
– and T lymphocytes, complementing *Ir* immune response genes, 906
– and T lymphocytes, reaction with anti-idiotypic antibody, 846
Bacteria, lipopolysaccharide, genetic linkage between mitogenic and adjuvant properties, 143
Bacteriocin determinants, transduction in Group A streptococci, 1540
Basophil hypersensitivity, cutaneous, genetic control, 206
–, IgE-sensitized, platelet-activating factor, platelet secretion, 937
–, IgE-sensitized, platelet-activating factor, role of serine proteases and cyclic nucleotides, 953
Blood groups, fractionation of A and H active glycoproteins, immunoadsorbents of *Dolichos* and *Lotus* lectins, 422
Bone marrow cells, transformation by Abelson murine leukemia virus, quantitative assay, 1453
Bordetella pertussis, leukocytosis- and lymphocytosis-promoting factor, 1483

C

Calcium modulation of Ig capping, cytoplasmic control of ligand-receptor complexes, 15
Capping, Ig, calcium modulation, cytoplasmic control of ligand-receptor complexes, 15
Carbohydrates, cell surface, antibody monovalent fragments, lymphocyte activation, 665
Carcinoma, thyroid medullary, amyloid fibril proteins, 993
Cation anesthetics, cell shape changes, 290
Caucasian, B-lymphocyte alloantigens, 981
Cell interactions, suppression of in vitro antibody response, 1421
– lines, histiocytic lymphoma, lysozyme synthesis, 1528
– shape changes, cationic anesthetics, 290
– surface carbohydrates, antibody monovalent fragments, lymphocyte activation, 665
Cell-mediated immune response, *I*-region control of suppressor and responder cell interaction, mixed lymphocyte reactions, 672
– immunity, delayed-type hypersensitivity and cytotoxic responses, T-cell subclasses, 1534
– immunity, host immune response, recovery from Friend virus leukemia, 85
– lympholysis, modified autologous lymphocytes, effector cell specificity controlled by *H-2K* and *H-2D* serological regions, 127
– lympholysis, modified autologous lymphocytes, use of anti-*H-2* and anti-Ia antibodies, 211
– lympholysis, role of *H-2* LD and SD factors, 1005
Cells, antierythrocyte plaque-forming, effect of concanavalin A-activated suppressor T cells, 919
–, autologous, induction of T-lymphocyte proliferation, 1042

Cells, B, immunocompetent antigen-binding, discrimination between immunity and tolerance, role of adherent cells, 805
–, B, neonatal murine, tolerance induction, 1327
–, B and T, Ia specificity, mitogen-induced blast cells, 218
–, bone marrow, transformation by Abelson murine leukemia virus, quantitative assay, 1453
–, Friend virus leukemia, erythroid differentiation, induction of heme pathway enzymes, 305
–, glial, and fibroblasts, human, specific surface antigen, loss in malignant cells, 64
–, *H-2* congenic, and minor H antigens, cross-priming for secondary cytotoxic response, 1283
–, human leukemic, membrane antigens, relation to oncogenic RNA virus components, 47
–, human lymphoid, fetal, surface antigens, 1557
–, human lymphoid, inhibition of Fc receptor by antisera of HLA system 1568
–, killer, comparison of natural immune T-cell- and antibody-dependent cellular cytotoxicity, 772
–, Kupffer, and macrophages, introduction of B-chain-inactivated ricin via membrane Fc receptors, 1464
–, leukemic, effects on antibody formation of syngeneic and allogeneic normal cells, 482
–, lymphoblastoid, human, and B lymphocytes, binding of properdin components, 271
–, lymphoid, murine, allogeneic reactions, α-fetoprotein synthesis, 1140
–, lymphoid, third molecular species of envelope protein gp70, murine leukemia virus, 969
–, mammalian, entry and intracellular fate of *Trypanosoma cruzi*, 1402
–, marrow-dependent, resistance of mitogen-responsive lymphocytes to Friend virus leukemia mediated by, 713
–, pancreatic beta, encephalomyocarditis viral replication, genetic host differences, 1171
–, precommitted, lymphocyte proliferation by leukocyte dialysates, 791
–, precursor, generation of cytotoxic lymphocytes, 1562
–, 19S and 7S antibody-forming, C3 receptors, 1111
–, spleen, lipopolysaccharide activation of antibodies against thymus-dependent antigen, 1429
–, suppressor, assay conditions and function of, 1211
–, suppressor, concanavalin A-treated normal lymphocytes, 1100
–, suppressor and responder interaction, mixed lymphocyte reactions, *I*-region control, 672
–, T, antiviral function, poxvirus infection, *H-2K* genetic element, 450
–, T, binding to alloantigens, mixed lymphocyte reaction, 648
–, T, cytotoxicity, preimmunization with *M* locus and *H-2* incompatibilities, 456
–, T effector, antigen recognition and cytolysis, 684
–, T, homing capacity, mitogen responsiveness, chromosome markers, 660
–, T, IgE antibody suppression, SJL mice, 833
–, T, independent antigen lipopolysaccharide, mitogenicity and immunogenicity, 1521
–, T lymphocytes, response to ectromelia virus infection, feedback suppression, 469
–, T, phytohemagglutinin- and concanavalin A-reactive, effects of anti-Ia sera, 372
–, T, resistance of mitogen-responsive lymphocytes to Friend virus leukemia mediated by, 728
–, T suppressor, concanavalin A-activated, effect on antierythrocyte plaque-forming cells, 919
–, T, suppressor and helper subclasses, activation by antigen, 1391
–, T, suppressor and helper subclasses, polyclonal activation, 1382
–, T, syngeneic, lysis of tumor cells, role of *H-2* antigens, 601
–, target, *H-2* incompatible, virus and trinitrophenol hapten-specific T-cell cytotoxicity, 999
–, tumor, lysis by syngeneic T cells, role of *H-2* antigens, 601
–, virus-infected, injury of, antiviral antibody and complement, role of IgG, Fab'2, and alternate complement pathway, 1027
Chemiluminescence and superoxide anion, human monocyte phagocytosis and contact with surface-bound immunoglobulin G, 1551
Chemotaxis, induction by collagen and collagen peptide, human blood monocytes, 1299
– and induction of neutrophil lysosomal enzyme secretion, synthetic peptides, 1154
Chlorpromazine, effects on generation and effector function of cytotoxic lymphocytes, 232
Chromosome markers, mitogen-responsive T cells, homing capacity, 660
Circulating factor suppression of macrophage-mediated resistance to infection, 559
Cis-trans effects and inclusion group systems, complementing *Ir* genes, 889
Clone size and clonotype analysis, antibody response of blood lymphocytes to streptococcal Group A polysaccharide antigens, 360
Clones, B lymphocytes, growth in semisolid culture, role of mitogen, 1265
Coformycin inhibition, human precursor lymphocyte maturation and adenosine deaminase, 1271
Colchicine stimulation of pyrogen production, human blood leukocytes, 1015
Collagen and collagen peptide induction of chemotaxis, human blood monocytes, 1299

Colony-stimulating factor and macrophage growth factor, 631
Compatibility, *H-2*, virus-specific T-cell-mediated cytolysis, 437
Complement and antiviral antibody, injury of virus-infected cells, role of IgG, Fab'2, and alternate complement pathway, 1027
– C3 receptors, 19S and 7S antibody-forming cells, 1111
– C8, three polypeptide chain structure, membrane attack mechanism, 1131
–, nonspecific activation, streptococcal structures, HLA cytotoxicity inhibition, 1341
–, nonspecific activation, streptococcal structures, properdin-independent initiation of alternate pathway, 1352
–, second component, synthesis by cultured human monocytes, 114
–, third component, interaction with human properdin, 241
Complex, antigen-antibody, adherence of Fc receptor-bearing lymphocytes, 329
–, ligand-receptor, cytoplasmic control of, calcium modulation of Ig capping, 15
–, major histocompatibility, alloantigen characteristics, guinea pig, 541
–, outer membrane, and serotypic specificity, *Neisseria gonorrhoeae*, 741
Concanavalin A activation of suppressor T cells, effect on antierythrocyte plaque-forming cells, 919
– A, effect on syngeneic response, murine lymphocytes, 1
– A- and phytohemagglutinin-reactive T cells, effects of anti-Ia sera, 372
– A treatment of normal lymphocytes, suppressor cell activity, 1100
Coxsackie Group B virus, role of diabetic gene in susceptibility to, 1239
Cross-priming, secondary cytotoxic response, minor H antigens and *H-2* congenic cells, 1283
Culture, semisolid, B-lymphocyte clone growth, role of mitogen, 1265
Cytolysis and antigen recognition, effector T cells, 684
–, T-cell-mediated, virus-specific, *H-2* compatibility, 437
Cytoplasm, control of ligand-receptor complexes, calcium modulation of Ig capping, 15
Cytotoxicity and delayed-type hypersensitivity, T-cell subclasses, 1534
–, frequency of lymphocyte precursor cells, 1562
–, HLA inhibition, nonspecific complement activation by streptococcal structures, 1341
–, killer cells, comparison of natural immune T-cell- and antibody-dependent system, 772
–, lymphocyte generation and effector function, effect of chlorpromazine, 232
–, secondary response, cross-priming, minor H antigens and *H-2* congenic cells, 1283
Cytotoxicity, T cell, virus and trinitrophenol hapten-specific, *H-2* incompatible target cells, 1099
–, T cells, preimmunization with *M* locus and *H-2* incompatibilities, 456

D

Deoxyribonucleic acid, phytohemagglutinin-stimulated lymphocytes, 1249
Diabetes gene, and susceptibility to Group B Coxsackie virus, 1239
– mellitus, juvenile, HLA system in families of patients with, 1277
– mellitus, virus-induced, genetic host differences in encephalomyocarditis viral replication, pancreatic beta cells, 1170
Dialysates, leukocyte, lymphocyte proliferation, precommitted cells, 791
Dolichos biflorus lectin, immunoadsorbent, fractionation of A and H active glycoproteins, blood groups, 422

E

γE production, effect of anti-mu suppression of γM and γG, 781
Effector function, cytotoxic lymphocytes, effect of chlorpromazine, 232
– T cells, antigen recognition and cytolysis, 684
Encephalomyocarditis virus replication, pancreatic beta cells, genetic host differences, 1170
Endotoxin, increased heterogeneity of affinity of immune response, fetal B lymphocytes, 1503
–, induced amyloidosis, amyloid-related serum protein SAA, mink, 678
Enterovirus infection, treatment with 2-(α-hydroxybenzyl)-benzimidazole and guanidine, 1367
Envelope protein gp70, third molecular species, murine leukemia virus, 969
Enzyme adenosine deaminase, human precursor lymphocyte maturation, inhibition by coformycin, 1271
–, lysosomal, and chemotaxis, neutrophils, effect of synthetic peptides, 1154
Enzymes, heme pathway, induction during erythroid differentiation, Friend virus leukemia cells, 305
Epithelial cell binding by lipoteichoic acid after M protein removal, Group A streptococcal fimbriae, 759
Erythrocyte specific helper activity, thoracic duct lymphocytes, reactivity to histocompatibility alloantigens, 701
Erythroid differentiation, Friend virus leukemia cells, induction of heme pathway enzymes, 305

F

Fab'2, IgG, and alternate complement pathway, role in injury of virus-infected cells, 1027
Fabry's disease, acid hydrolases, leukocytes and platelets, 975
Factor, chemotactic, and induction of neutrophil lysosomal enzyme secretion, synthetic peptides, 1154
–, circulating, suppression of macrophage-mediated resistance to infection, 559
–, *H-2* LD and SD, role in cell-mediated lympholysis, 1005
–, leukocytosis- and lymphocytosis-promoting, *Bordetella pertussis*, 1483
–, macrophage growth and colony-stimulating, 631
–, platelet-activating, from IgE-sensitized basophils, platelet secretion, 937
–, platelet-activating, from IgE-sensitized basophils, role of serine proteases and cyclic nucleotides, 953
Fc receptor, associated Ag-B antigens, role in allograft enhancement, 405
– receptor, human lymphoid cells, inhibition by antisera of HLA system, 1568
– receptor-bearing lymphocytes, adherence to antigen-antibody complexes, 329
– receptors, membrane, introduction of B-chain-inactivated ricin into macrophages and Kupffer cells, 1464
Fetal B lymphocytes, endotoxin and increased heterogeneity of affinity of immune response, 1503
α-Fetoprotein synthesis in allogeneic reactions, murine lymphoid cells, 1140
Fetus, human lymphoid cells, surface antigens, 1557
–, sheep, lymphopoiesis and lymphocyte recirculation, 167
Fibril proteins, amyloid, thyroid medullary carcinoma, 993
Fibroblasts and glial cells, human, specific surface antigen, loss in malignant cells, 64
–, human, α_2-macroglobulin synthesis, 462
Fimbriae, Group A streptococci, epithelial cell binding by lipoteichoic acid after M protein removal, 759
Friend virus leukemia cells, erythroid differentiation, induction of heme pathway enzymes, 305
– virus leukemia, genetic resistance, mitogen-responsive lymphocytes mediated by marrow-dependent cells, 713
– virus leukemia, genetic resistance, mitogen-responsive lymphocytes mediated by T cells, 728
– virus leukemia, host immune response, antiviral and antileukemia cell antibodies, 73
– virus leukemia, host immune response, cell-mediated immunity, 85

G

Gangliosides, markers for murine lymphocyte subpopulations, 822
Gaucher's disease, acid hydrolases, leukocytes and platelets, 975
Gene, diabetes, and susceptibility to Group B Coxsackie virus, 1239
– expression, oncornaviral, glycoprotein gp70, 151
– V_H control of antibody specificity, azobenzenearsonate-hydroxyphenylacetic acid, 316
Genes, *Ir*, B- and T-lymphocyte immune response, 906
–, *Ir* complementing, inclusion group systems and *cis-trans* effects, 889
–, *Ir* complementing, T-lymphocyte response to poly(Glu,Lys,Phe), 897
Genetic control, antigen-induced T-lymphocyte proliferation, murine peritoneal exudate, 529
– control, cell-mediated lympholysis, modified autologous lymphocytes, use of anti-*H-2* and anti-Ia antibodies, 211
– control, cutaneous basophil hypersensitivity, 206
– control, T-helper cell response to anti-idiotypic antibody, 861
– crosses, relationship of murine leukemia virus and virus-related antigens, 32
– element, *H-2K*, T-cell antiviral function in poxvirus infection, 450
– host differences in encephalomyocarditis viral replication, pancreatic beta cells, 1170
– linkage between mitogenic and adjuvant properties, bacterial lipopolysaccharide, 143
– polymorphism, rabbit b4 kappa chains, 1475
– resistance to Friend virus leukemia, mitogen-responsive lymphocytes mediated by marrow-dependent cells, 713
– resistance to Friend virus leukemia, mitogen-responsive lymphocytes mediated by T cells, 728
– resistance to mouse hepatitis virus, in vitro conversion of macrophages, 690
Glial cells and fibroblasts, human, specific surface antigen, loss in malignant cells, 64
Glycoprotein gp70, oncornaviral gene expression, 151
Glycoproteins, A and H, blood groups, fractionation on immunoadsorbents of *Dolichos* and *Lotus* lectins, 422
Grafts, skin, incompatible with skin alloantigens, 1317
Granuloma formation, adoptive suppression, 696
Growth factor, macrophage, and colony-stimulating factor, 631
Guanidine and 2-(α-hydroxybenzyl)-benzimidazole treatment of enterovirus infection, 1367
Guinea pig L2C leukemia, Ia alloantigens and

tumor-associated transplantation antigens, 1067

H

H-2-activated T lymphocytes, IgM antibody adsorption, 444
– antigens, lysis of tumor cells by syngeneic T cells, 601
– compatibility, virus-specific T-cell-mediated cytolysis, 437
– congenic cells and minor H antigens, cross-priming for secondary cytotoxic response, 1283
– determinants, recirculating lymphocytes, effect of antigen priming on adoptive immune response, 585
– incompatible target cells, virus and trinitrophenol hapten-specific T-cell cytotoxicity, 999
– LD and SD factors, role in cell-mediated lympholysis, 1005
– and *M* locus incompatibilities, preimmunization, T-cell cytotoxicity, 456
H-2A and *H-2C* loci, mapping of, *I*-region control of histocompatibility antigens, 1439
H-2K genetic element, T-cell antiviral function in poxvirus infection, 450
– and *H-2D* serological regions, control of cell-mediated lympholysis, N-modified autologous lymphocytes, 127
Hapten-specific B lymphocytes, antigen effects on receptors, 511
Helper and suppressor T lymphocytes, separation on Ficoll velocity sedimentation gradient, 1199
Hematopoiesis, thymocyte precursors, kinetics of progeny appearance, 1082
Heme pathway enzymes, induction during erythroid differentiation, Friend virus leukemia cells, 305
Hepatitis virus, in vitro conversion of genetic resistant macrophages, 690
Histocompatibility alloantigens, thoracic duct lymphocytes reactive to, erythrocyte-specific helper activity, 701
– antigens, control by *I* region, mapping of *H-2A* and *H-2C* loci, 1439
– complex, *H-2K* and *H-2D* regions, control of cell-mediated lympholysis, N-modified autologous lymphocytes, 127
– complex, major, alloantigen characteristics, guinea pig, 541
HLA cytotoxicity inhibition, nonspecific complement activation by streptococcal structures, 1341
– system antisera, inhibition of human lymphoid cell Fc receptor, 1568
– system, families of patients with juvenile diabetes mellitus, 1277
Homing capacity, mitogen-responsive T cells, chromosome markers, 660
Host defense mechanism subversion by tumor, circulating factor suppression of macrophage-mediated resistance to infection, 559
– defense mechanism subversion by tumor, effect of concomitant antitumor immunity, 574
– genetic differences in encephalomyocarditis viral replication, pancreatic beta cells, 1170
– immune response, recovery from Friend virus leukemia, antiviral and antileukemia cell antibodies, 73
– immune response, recovery from Friend virus leukemia, cell-mediated immunity, 85
Hydrolases, acid, leukocytes and platelets, Gaucher's and Fabry's disease, 975
2-(α-Hydroxybenzyl)-benzimidazole and guanidine, treatment of enterovirus infection, 1367
Hydroxyphenylacetic acid-azobenzenearsonate, V_H gene control of antibody specificity, 316
Hypersensitivity, cutaneous basophil, genetic control, 206
–, delayed-type, and cytotoxic responses, T-cell subclasses, 1534

I

I-region control of histocompatibility antigens, mapping of *H-2A* and *H-2C* loci, 1439
– region control of suppressor and responder cell interaction, mixed lymphocyte reactions, 672
Ia alloantigens and tumor-associated transplantation antigens, guinea pig L2C leukemia, 1067
–, Ib, and Ic types Group B streptococci, interaction of serum and macrophages with, 1186
– marker, phytohemagglutinin- and concanavalin A-reactive T cells, 372
– specificity, T and B cells, mitogen-induced blast cells, 218
Idiotype analysis, B and T lymphocytes specificity and heterogeneity, 846
– analysis, genetic control of T-helper cell response, 861
IgE antibody suppression, SJL mice, 833
IgE-sensitized basophils, platelet-activating factor, platelet secretion, 937
– basophils, platelet-activating factor, role of serine proteases and cyclic nucleotides, 953
Immune complex orchitis, vasectomy, 382
– precipitates, solubilization by serum, 615
– response, adoptive, antigen-initiated B-lymphocyte differentiation, 1220
– response, adoptive, effect of antigen priming, lymphocyte recirculation to spleen, 1289
– response, adoptive, effect of antigen priming, subsets of *H-2*-reactive T cells, 585
– response, antibody cyclical production, regulatory mechanisms, 497
– response, B and T lymphocytes, *Ir* genes, 906
– response, cell-mediated, *I*-region control of suppressor and responder interaction, mixed lymphocyte reactions, 672

Immune response, fetal B lymphocytes, endotoxin and increased heterogeneity of affinity, 1503
– response, host, recovery from Friend virus leukemia, antiviral and antileukemic cell antibodies, 73
– response, host, recovery from Friend virus leukemia, cell-mediated immunity, 85
– response, inclusion group systems and *cis-trans* effects, complementing *Ir* genes, 889
– response, T-lymphocyte proliferation and poly(Glu,Lys,Phe), complementing *Ir* genes, 897
Immunity, antitumor, subversion of host defense mechanism by tumor, 574
–, cell-mediated, delayed-type hypersensitivity and cytotoxic responses, T-cell subclasses, 1534
– and tolerance, discrimination by antigen-binding immunocompetent B cells, 805
Immunization, antigen-specific suppressor and helper T-cell subclasses, 1391
Immunoadsorbents, *Dolichos* and *Lotus* lectins, fractionation of A and H active glycoproteins, blood groups, 422
Immunocompetent B-cell antigen-binding, discrimination between immunity and tolerance, role of adherent cells, 305
Immunogenicity and mitogenicity, T-independent antigen lipopolysaccharide, 1521
Immunoglobulin capping, calcium modulation, cytoplasmic control of ligand-receptor complexes, 15
– G contact and phagocytosis, human monocytes, superoxide anion and chemiluminescence during, 1551
– G, Fab'2, and alternate complement pathway, role in injury of virus-infected cells, 1027
– isotypes, B-lymphocyte surface, 1055
– M antibody absorption onto *H-2*-activated T lymphocytes, 444
–, surface, and IgG memory, thoracic duct lymph, 1122
Immunoperoxidase labeling of alloantigens, preimplantation development and trophoblast differentiation, 348
Immunosuppression, mouse EL-4 lymphoma subline, minute virus of mice, 187
Inclusion group systems and *cis-trans* effects, complementing *Ir* genes, 889
Incompatibility, skin grafts and alloantigens, 1317
Infection, ectromelia virus, T-cell antiviral function, *H-2K* genetic element, 450
–, ectromelia virus, T-cell feedback suppression, 469
–, enterovirus, treatment with 2-(α-hydroxybenzyl)-benzimidazole and guanidine, 1367
Injury of virus-infected cells, antiviral antibody and complement, role of IgG, Fab'2, and alternate complement pathway, 1027
Ir genes, B- and T-lymphocyte immune response, 906
– genes, complementing, inclusion group systems and *cis-trans* effects, 889
– genes, complementing, T-lymphocyte response to poly(Glu,Lys,Phe), 897

K

Kappa b4 chain, rabbit, genetic polymorphism, 1475
Killer cells, comparison of natural immune T-cell and antibody-dependent cellular cytotoxicity, 772
Kupffer cells and macrophages, introduction of B-chain-inactivated ricin via membrane Fc receptors, 1464

L

Lactic dehydrogenase virus, inhibition of lymphocyte trapping, ascites tumor, 100
Lectins, *Dolichos* and *Lotus*, immunoadsorbent, fractionation of A and H active glycoproteins, blood groups, 422
Leukemia, effect on antibody-forming potential of syngeneic and allogeneic normal cells, 482
–, Friend virus, cell erythroid differentiation, induction of heme pathway enzymes, 305
–, Friend virus, genetic resistance, mitogen-responsive lymphocytes mediated by marrow-dependent cells, 713
–, Friend virus, genetic resistance, mitogen-responsive lymphocytes mediated by T cells, 728
–, Friend virus, host immune response, antiviral and antileukemia cell antibodies, 73
–, Friend virus, host immune response, cell-mediated immunity, 85
–, guinea pig L2C, Ia alloantigens and tumor-associated transplantation antigens, 1067
–, myelogenous, human cell transplantation, hereditary asplenic-athymic mice, 225
– virus, Abelson, bone marrow cell transformation, quantitative assay, 1453
– virus, murine, third molecular species of envelope protein gp70, 969
– virus, murine, and virus-related antigens, relationship in genetic crosses, 32
Leukocyte dialysates, lymphocyte proliferation, precommitted cells, 791
Leukocytes, human, pyrogen production, colchicine stimulation of, 1015
– and platelets, acid hydrolases, Gaucher's and Fabry's disease, 975
–, polymorphonuclear, human, phagocytosis, role of membrane sialic acid in superoxide production, 1308
Leukocytosis-promoting factor, *Bordetella pertussis*, 1483
Ligand-receptor complex, cytoplasmic control of, calcium modulation of Ig capping, 15
Lipopolysaccharide activation of spleen cell antibodies against thymus-dependent antigen, 1429

Lipopolysaccharide, bacterial, genetic linkage between mitogenic and adjuvant properties, 143
–, T-independent antigen, mitogenicity and immunogenicity, 1521
Lipoteichoic acid, epithelial cell binding, Group A streptococcal fimbriae after M protein removal, 759
Loci, *H-2A* and *H-2C*, mapping of, *I*-region control of histocompatibility antigens, 1439
Lotus tetragonolobus lectin, immunoadsorbent, fractionation of A and H active glycoproteins, blood groups, 422
Lymph node secretion, antipolysaccharide antibodies, restricted heterogeneity, 707
– node, single, effect of antigen on lymphocyte recirculation through, 870
–, thoracic duct, surface immunoglobulins, and IgG memory, 1122
Lymphocyte activation by antibody monovalent fragments, cell surface carbohydrates, 665
–, mixed reactions, *I*-region control of suppressor and responder cell interaction, 672
– proliferation by leukocyte dialysates, precommitted cells, 791
– recirculation, *H-2*-reactive subsets, effect of antigen priming on adoptive immune response, 585
– recirculation and lymphopoiesis, sheep fetus, 167
– recirculation through single lymph node, effect of antigen, 870
– recirculation to spleen, effect of antigen priming on adoptive immune responses, 1289
– subpopulations, murine, ganglioside markers, 822
– trapping, inhibition by lactic dehydrogenase virus, ascites tumor, 100
Lymphocytes, B, alloantigens, Caucasians, 981
–, B, clone growth in semisolid culture, role of mitogen, 1265
–, B, differentiation, antigen-initiated, adoptive immune response, 1220
–, B, fetal, endotoxin and increased heterogeneity of affinity of immune response, 1503
–, B, hapten-specific, antigen effects on receptors, 511
–, B, and lymphoblastoid cells, binding of properdin components, 271
–, B, surface immunoglobulin isotypes, 1055
–, B and T, complementing *Ir* immune response genes, 906
–, B and T, Ia specificity, mitogen-induced blast cells, 218
–, B and T, reaction with anti-idiotypic antibody, 846
–, blood, antibody response to streptococcal Group A polysaccharide antigens, 360
–, concanavalin A-treated, suppressor cell activity, 1100
–, cytotoxic, frequency of precursor cells, 1562
Lymphocytes, cytotoxic, generation and effector function, effect of chlorpromazine, 232
–, Fc receptor-bearing, adherence to antigen-antibody complexes, 329
–, human precursor, coformycin inhibition of maturation and adenosine deaminase, 1271
–, mitogen-responsive, genetic resistance to Friend virus leukemia mediated by marrow-dependent cells, 728
–, mitogen-responsive, genetic resistance to Friend virus leukemia mediated by T cells, 728
–, modified autologous, cell-mediated lympholysis, effector cell specificity controlled by *H-2K* and *H-2D* serological regions, 127
–, modified autologous, cell-mediated lympholysis, use of anti-*H-2* and anti-Ia antibodies, 211
–, murine, syngeneic response, effect of concanavalin A, 1
–, phytohemagglutinin-stimulated, DNA characterization, 1249
–, T, antigen-induced proliferation, genetic control, murine peritoneal exudate, 529
–, T, *H-2*-activated, IgM antibody adsorption, 444
–, T, helper and suppressor, separation on Ficoll velocity sedimentation gradient, 1199
–, T, proliferation induced by autologous or allogeneic non-T lymphocytes, 1042
–, T, response to poly(Glu,Lys,Phe), complementing *Ir* genes, 897
–, thoracic duct, erythrocyte-specific helper activity, reactivity to histocompatibility alloantigens, 701
Lymphocytosis-promoting factor, *Bordetella pertussis*, 1483
Lymphoid cells, murine, allogeneic reactions, α-fetoprotein synthesis, 1140
Lympholysis, cell-mediated, modified autologous lymphocytes, effector cell specificity controlled by *H-2K* and *H-2D* serological regions, 127
–, cell-mediated, modified autologous lymphocytes, use of anti-*H-2* and anti-Ia antibodies, 211
–, cell-mediated, role of *H-2* LD and SD factors, 1005
Lymphoma cell lines, histiocytic, lysozyme synthesis, 1528
–, mouse EL-4 subline, immunosuppression, minute virus of mice, 187
Lymphopoiesis and lymphocyte recirculation, sheep fetus, 167
Lysosomes, neutrophils, enzyme induction, chemotaxis, synthetic peptides, 1154
Lysozyme synthesis, histiocytic lymphoma cell lines, 1528

M

γM and γG, anti-mu suppression, effect on γE, 781

M locus and *H-2* incompatibilities, preimmunization, T-cell cytotoxicity, 456
M protein removal, Group A streptococci fimbriae, epithelial cell binding by lipoteichoic acid, 759
α_2-Macroglobulin synthesis, human fibroblasts, 462
Macrophage, genetic resistance to mouse hepatitis virus, in vitro conversion, 690
– growth factor and colony-stimulating factor, 631
– and Kupffer cells, introduction of B-chain-inactivated ricin via membrane Fc receptors, 1464
– resistance to infection, suppression by circulating factor, tumor subversion of host defense mechanism, 559
– and serum interaction with Group B streptococci types Ia, Ib, and Ic, 1186
Man, blood leukocytes, pyrogen production, colchicine stimulation of, 1015
–, cultured monocytes, synthesis of complement second component, 114
–, Fc receptor-bearing lymphocytes, adherence to antigen-antibody complexes, 329
–, fibroblasts, α_2-macroglobulin synthesis, 462
–, glial cells and fibroblasts, specific surface antigen, loss in malignant cells, 64
–, leukemic cells, membrane antigens, relation to oncogenic RNA virus components, 47
–, lymphoblastoid cells and B lymphocytes, binding of properdin components, 271
–, lymphocyte precursor, coformycin inhibition of maturation and adenosine deaminase, 1271
–, lymphoid cells, fetal, surface antigens, 1557
–, lymphoid cells, inhibition of Fc receptor by antisera of HLA system, 1568
–, monocytes, chemotaxis induction by collagen and collagen peptide, 1299
–, monocytes, phagocytosis and contact with surface-bound immunoglobulin G, superoxide anion and chemiluminescence during, 1551
–, myelogenous leukemic cell transplantation, hereditary asplenic-athymic mice, 225
–, polymorphonuclear leukocytes, phagocytosis, role of membrane sialic acid in superoxide production, 1308
–, properdin, multiple sedimenting species, interaction with complement third component, 241
–, T-lymphocyte proliferation induced by autologous or allogeneic non-T lymphocytes, 1042
Mapping, *H-2A* and *H-2C* loci, *I*-region control of histocompatibility antigens, 1439
Markers, gangliosides, murine lymphocyte subpopulations, 822
Membrane antigens, human leukemia cells, relation to oncogenic RNA virus components, 47
Membrane attack mechanism, complement C8, three polypeptide chain structure, 1131
– complex, outer, and serotypic specificity, *Neisseria gonorrhoeae*, 741
– Fc receptors, introduction of B-chain-inactivated ricin into macrophages and Kupffer cells, 1464
– sialic acid, role in superoxide production, phagocytosis by human polymorphonuclear leukocytes, 1308
Memory, IgG, and surface immunoglobulins, thoracic duct lymph, 1122
Mink, endotoxin-induced amyloidosis, amyloid-related serum protein SAA, 678
Mitogen and adjuvant activity, genetic linkage between, bacterial lipopolysaccharide, 143
– effect on blast cells, Ia specificity, T and B cells, 218
– response, effects of anti-Ia sera, phytohemagglutinin- and concanavalin A-reactive T cells, 372
–, responsive lymphocytes, genetic resistance to Friend virus leukemia mediated by marrow-dependent cells, 713
–, responsive lymphocytes, genetic resistance to Friend virus leukemia mediated by T cells, 728
– responsiveness, homing capacity of T cells, chromosome markers, 660
–, role in B-lymphocyte clone growth in semisolid culture, 1265
Mitogenicity and immunogenicity, T-independent antigen lipopolysaccharide, 1521
Mixed lymphocyte reaction, alloantigen binding to T cells, 648
Monocytes, cultured, human, synthesis of complement second component, 114
–, human, chemotaxis induction by collagen and collagen peptide, 1299
–, human, phagocytosis and contact with surface-bound immunoglobulin G, superoxide anion and chemiluminescence during, 1551

N

Neisseria gonorrhoeae, outer membrane complex and serotypic specificity, 741
Neonatal induction, in vitro tolerance, 1545
– murine B cells, tolerance induction, 1327
Neutrophil lysosomal enzyme induction, chemotaxis. synthetic peptides, 1154
Nucleotides, cyclic, and serine proteases, role in platelet-activating factor-induced platelet secretion, 953

O

Oncornavirus gene expression, glycoprotein gp70, 151
Ontogeny, B-lymphocyte function, effect of endotoxin, 1
Orchitis, immune complex, vasectomy, 382

P

Pancreas beta cells, encephalomyocarditis viral replication, genetic host differences, 1170
Peptide, collagen, induction of chemotaxis, human blood monocytes, 1299
Peptides, synthetic, chemotactic factors, induction of neutrophil lysosomal enzyme secretion, 1154
Peritoneal exudate, murine, antigen-induced T-lymphocyte proliferation, genetic control, 529
Phagocytosis and contact with surface-bound immunoglobulin G, human monocytes, superoxide anion and chemiluminescence during, 1551
–, human polymorphonuclear leukocytes, role of membrane sialic acid in superoxide production, 1308
Phytohemagglutinin- and concanavalin A-reactive T cells, effects of anti-Ia sera, 372
– stimulation of lymphocytes, DNA characterization, 1249
Pig, tissue differences in major transplantation antigens, organ allografts, 987
Plaque-forming cells, antierythrocyte, effect of concanavalin A-activated suppressor T cells, 919
Platelet-activating factor from IgE-sensitized basophils, platelet secretion, 937
– factor from IgE-sensitized basophils, role of serine proteases and cyclic nucleotides, 953
Platelets and leukocytes, acid hydrolases, Gaucher's and Fabry's disease, 975
Polyclonal activation, T-cell suppressor and helper subclasses, 1382
Poly(Glu,Lys,Phe), T-lymphocyte response to, complementing *Ir* genes, 897
Polymorphism, genetic, rabbit b4 kappa chains, 1475
Polypeptide chain structure, complement C8, membrane attack mechanism, 1131
Polysaccharide, anti-, antibodies, restricted heterogeneity, secretion by single lymph node, 707
– antigens, streptococcal Group A, antibody response of blood lymphocytes, 360
–, native type III, Group B *Streptococcus*, immunochemical characterization, 256
Precipitates, immune, solubilization by serum, 615
Precommitted cells, lymphocyte proliferation by leukocyte dialysates, 791
Precursor cells, generation of cytotoxic lymphocytes, 1562
Preimplantation development and trophoblast differentiation, immunoperoxidase labeling of alloantigens, 348
Progeny, kinetics of appearance, hematopoietic thymocyte precursors, 1082
Properdin components, binding to human lymphoblastoid cells and B lymphocytes, 271
Properdin independent initiation of alternate pathway, nonspecific complement activation by streptococcal structures, 1352
–, multiple sedimenting species, interaction with human complement third component, 241
Proteases, serine, and cyclic nucleotides, role in platelet-activating factor-induced platelet secretion, 953
Proteins, amyloid fibril, thyroid medullary carcinoma, 993
–, envelope, gp70, third molecular species, murine leukemia virus, 969
–, M, removal from Group A streptococcal fimbriae, epithelial cell binding by lipoteichoic acid, 759
– SAA, serum, amyloid-related, endotoxin-induced amyloidosis, mink, 678
Pyrogen production, human blood leukocytes, colchicine stimulation of, 1015

R

Receptor, Fc, human lymphoid cells, inhibition by antisera of HLA system, 1568
– ligand complex, cytoplasmic control of, calcium modulation of Ig capping, 15
Receptors, C3, 19S and 7S antibody-forming cells, 1111
–, Fc, associated Ag-B antigens, role in allograft enhancement, 405
–, Fc, lymphocytes, adherence to antigen-antibody complexes, 329
–, Fc, membrane, introduction of B-chain-inactivated ricin into macrophages and Kupffer cells, 1464
–, hapten-specific B lymphocytes, effects of antigens, 511
Ribonucleic acid virus components, relation to membrane antigens of human leukemic cells, 47
Ricin, B-chain-inactivated, introduction into macrophages and Kupffer cells via membrane Fc receptors, 1464

S

Sedimentation, multiple, human properdin, interaction with complement third component, 241
– velocity, antigen-initiated B-lymphocyte differentiation, adoptive immune response, 1220
– velocity, separation of helper and suppressor T lymphocytes, 1199
Serum, anti-Ia, effects on mitogenic responses, phytohemagglutinin- and concanavalin A-reactive T cells, 372
–, human, multiple sedimenting properdin species, interaction with complement third component, 241
– and macrophage interaction with Group B streptococci types Ia, Ib, and Ic, 1186

Serum protein SAA, amyloid-related, endotoxin induced amyloidosis, mink, 678
– solubilization of immune precipitates, 615
Sialic acid, membrane, role in superoxide production, phagocytosis by human polymorphonuclear leukocytes, 1308
Skin, basophil hypersensitivity, genetic control, 206
– grafts incompatible with skin alloantigens, 1317
Solubilization of immune precipitates by serum, 615
Specificity, serotypic, and outer membrane complex *Neisseria gonorrhoeae*, 741
Spleen cells, lipopolysaccharide activation of antibodies against thymus-dependent antigen, 1429
–, recirculating lymphocytes, effect of antigen priming on adoptive immune responses, 1289
– and thymus, hereditary agenesis, transplantation of human myelogenous leukemic cells, 225
Streptococcus, Group A, epithelial cell binding by lipoteichoic acid, fimbriae lacking M protein, 759
– Group A polysaccharide antigens, antibody response of blood lymphocytes, 360
–, Group A, transduction of bacteriocin determinants, 1540
– Group B, immunochemical characterization of native type III polysaccharide, 256
– Group B, interaction of serum and macrophages with types Ia, Ib, and Ic, 1186
– nonspecific complement activation, HLA cytotoxicity inhibition, 1341
– nonspecific complement activation, properdin-independent initiation of alternate pathway, 1352
Superoxide anion and chemiluminescence, human monocyte phagocytosis and contact with surface-bound immunoglobulin G, 1551
– production, phagocytosis by human polymorphonuclear leukocytes, role of membrane sialic acid, 1308
Suppression, adoptive, granuloma formation, 696
–, anti-mu, of γM and γG, effect on γE, 781
–, feedback, T-cell response to ectromelia virus infection, 469
–, IgE antibody production, SJL mice, 833
–, immune, mouse EL-4 lymphoma subline, minute virus of mice, 187
– of in vitro antibody responses, cell interactions, 1421
–, macrophage-mediated resistance to infection, circulating factor, tumor subversion of host defense mechanism, 559
Suppressor cells, assay conditions and function of, 1211
– cells, concanavalin A-treated normal lymphocytes, 1100
– and helper T-lymphocytes, separation on Ficoll velocity sedimentation gradient, 1199
Suppressor T cells, concanavalin A-activated, effect on antierythrocyte plaque-forming cells, 919
Surface antigens, fetal human lymphoid cells, 1557
– carbohydrates, antibody monovalent fragments, lymphocyte activation, 665
– immunoglobulin and IgG memory, thoracic duct lymph, 1122
– immunoglobulin isotypes, B lymphocytes, 1055
– specific antigen, human glial cells and fibroblasts, loss in malignant cells, 64
Syngeneic and allogeneic normal cells, effect of leukemic cells on antibody formation, 482
– response, murine lymphocytes, effect of concanavalin A, 1
– T-cell lysis of tumor cells, role of *H-2* antigens, 601

T

T and B lymphocytes, complementing *Ir* immune response genes, 906
– and B lymphocytes, reaction with anti-idiotypic antibody, 846
– cell antiviral function, poxvirus infection, *H-2K* genetic element, 450
– cell binding to alloantigens, mixed lymphocyte reaction, 648
– cell cytotoxicity, preimmunization with *M* locus and *H-2* incompatibilities, 456
– cell cytotoxicity, virus and trinitrophenol hapten-specific, *H-2* incompatible target cells, 999
– cell feedback suppression, ectromelia virus infection, 469
– cell homing capacity, mitogen responsiveness, chromosome markers, 660
– cell, natural immune, and antibody-dependent cellular cytotoxicity, comparison of killer cells, 771
– cell subclasses, delayed-type hypersensitivity and cytotoxic responses, 1534
– cell suppressor and helper subclasses, activation by antigen, 1391
– cell suppressor and helper subclasses, polyclonal activation, 1382
– cell-mediated cytolysis, virus-specific, *H-2* compatibility, 437
– cells, effector, antigen recognition and cytolysis, 684
– cells, Ia specificity, mitogen-induced blast cells, 218
– cells, IgE antibody suppression, SJL mice, 833
– cells, independent antigen lipopolysaccharide, mitogenicity and immunogenicity, 1521
– cells, phytohemagglutinin- and concanavalin A-reactive, effects of anti-Ia sera, 372
– cells, suppressor, concanavalin A-activated, effect on antierythrocyte plaque-forming cells, 919

T cells, syngeneic, lysis of tumor cells, role of *H-2* antigens, 601
– helper cell response to anti-idiotypic antibody, genetic control, 861
– lymphocytes, antigen-induced proliferation, genetic control, murine peritoneal exudate, 529
– lymphocytes, *H-2*-activated, IgM antibody adsorption, 444
– lymphocytes, helper and suppressor, separation on Ficoll velocity sedimentation gradient, 1199
– lymphocytes, proliferation induced by autologous or allogeneic non-T lymphocytes, 1042
– lymphocytes response to poly(Glu,Lys,Phe), complementing *Ir* genes, 897
Thoracic duct lymph, surface immunoglobulins and IgG memory, 1122
Thymocyte precursors, hematopoietic, kinetics of progeny appearance, 1082
Thymus and spleen, hereditary agenesis, transplantation of human myelogenous leukemic cells, 225
Thymus-dependent antigen, lipopolysaccharide activation of, spleen cell antibodies against, 1429
Thyroid medullary carcinoma, amyloid fibril proteins, 993
Tissue differences, major transplantation antigens, organ allografts, pig, 987
Tolerance and immunity, discrimination by antigen-binding immunocompetent B cells, 805
– in vitro, neonatal induction, 1545
– induction, neonatal murine B cells, 1327
Transduction, bacteriocin determinants, Group A streptococci, 1540
Transplantation antigens, tissue differences, pig, 986
– antigens, tumor-associated, and Ia alloantigens, guinea pig L2C leukemia, 1067
–, human myelogenous leukemic cells, hereditary asplenic-athymic mice, 225
Trapping, lymphocytes, inhibition by lactic dehydrogenase virus, ascites tumor, 100
Trinitrophenol hapten-specific cytotoxic lymphocytes, *H-2* incompatible target cells, 999
Trophoblast differentiation and preimplantation development, immunoperoxidase labeling of alloantigens, 348
Trypanosoma cruzi, entry and intracellular fate in mammalian cells, 1402
Tumor, ascites, lactic dehydrogenase virus inhibition of lymphocyte trapping, 100
– cell lysis by syngeneic T cells, role of *H-2* antigens, 601

V

Vasectomy, immune complex orchitis, 382
Virus components, oncogenic RNA, relation to membrane antigens of human leukemic cells, 47
–, ectromelia infection, T-cell antiviral function, *H-2K* genetic element, 450
–, ectromelia infection, T-cell feedback suppression, 469
–, encephalomyocarditis, replication in pancreatic beta cells, genetic host differences, 1170
–, Friend, leukemia cells, erythroid differentiation, induction of heme pathway enzymes, 305
–, Friend, leukemia, genetic resistance, mitogen-responsive lymphocytes mediated by marrow-dependent cells, 713
–, Friend, leukemia, genetic resistance, mitogen-responsive lymphocytes mediated by T cells, 728
–, Friend leukemia, host immune response, antiviral and antileukemia cell antibodies, 73
–, Friend, leukemia, host immune response, cell-mediated immunity, 85
– glycoprotein, endogenous gene expression, 151
–, Group B Coxsackie, role of diabetic gene in susceptibility to, 1239
– hapten-specific cytotoxic lymphocytes, *H-2* incompatible target cells, 999
–, hepatitis, in vitro conversion of genetic resistant macrophages, 690
– infection, cell injury by antiviral antibody and complement, role of IgG, Fab'2, and alternate complement pathway, 1027
–, lactic dehydrogenase, inhibition of lymphocyte trapping, ascites tumor, 100
–, leukemia, Abelson, bone marrow cell transformation, quantitative assay, 1453
–, minute, immunosuppression of mouse EL-4 lymphoma subline, 187
–, murine leukemia, third molecular species of envelope protein gp70, 969
–, murine leukemia, and virus-related antigens, relationship in genetic crosses, 32
Virus-specific T-cell-mediated cytolysis, *H-2* compatibility, 437

CORRECTION

L. Cohen, R. S. Holzman, F. S. Valentine, and H. S. Lawrence. *The Journal of Experimental Medicine*, Vol. 143, No. 4, April 1976

Page 801, Table VI

The box outlines were omitted by the printer in the final printing. See correct table below.

TABLE VI

Failure of Leukocyte Dialysates to Restore the Response of Lymphocyte Populations Depleted of Antigen-Reactive Cells

Antigen clone deleted	Secondary antigen without dialysates			Secondary antigen with dialysates		
	PPD	D.Tox.	SK-SD	PPD	D.Tox.	SK-SD
None	100*	100	100	279 ± 58	221 ± 38	254 ± 50
PPD	33 ± 14	75 ± 16	82 ± 20	49 ± 13	152 ± 32	132 ± 39
D.Tox.	95 ± 17	58 ± 21	98 ± 25	316 ± 100	63 ± 10	219 ± 45
SK-SD	87 ± 15	106 ± 25	26 ± 6	294 ± 84	370 ± 90	46 ± 8

* Percent of control stimulation ratio; each number represents the mean of 6 to 16 experiments ± the SE. Boxed percentages are significantly less than 100%.